<SEC-DOCUMENT>0001641172-25-021545.txt : 20250730
<SEC-HEADER>0001641172-25-021545.hdr.sgml : 20250730
<ACCEPTANCE-DATETIME>20250730160543
ACCESSION NUMBER:		0001641172-25-021545
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20250730
DATE AS OF CHANGE:		20250730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273829
		FILM NUMBER:		251166993

	BUSINESS ADDRESS:	
		STREET 1:		1044 NORTH U.S. HIGHWAY ONE
		STREET 2:		SUITE 201
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		1044 NORTH U.S. HIGHWAY ONE
		STREET 2:		SUITE 201
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and
the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any
state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-273829</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">SUBJECT
TO COMPLETION, DATED July 30, 2025</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
Prospectus Dated August 25, 2023)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="form424b5_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DYADIC
INTERNATIONAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, par value $0.001 per share, at a price to the public of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;DYAI.&rdquo; On July 29, 2025, the last reported sale
price of our common stock as reported on The Nasdaq Capital Market was $1.1750 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
Hazelton, our President and Chief Operating Officer, has indicated his preliminary interest in purchasing approximately $25,000 of shares
of our common stock in this offering at the public offering price. However, because indications of interest are not binding agreements
or commitments to purchase, the underwriter may determine to sell more, fewer or no shares in this offering to Mr. Hazelton, or Mr. Hazelton
may determine to purchase more, fewer or no shares in the offering. The underwriter will receive the same underwriting discount on any
shares of common stock purchased by Mr. Hazelton as they will on any other shares sold to the public in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public
    offering price</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions<SUP>(1)</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds,
    before expenses, to us</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; width: 25%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to reimburse the underwriter for certain expenses. See &ldquo;Underwriting&rdquo; on page S-23 of this prospectus supplement
    for additional disclosure regarding underwriter discounts, commissions and estimated offering expenses. We have also agreed to issue
    to the underwriter warrants to purchase up to 5.0% of the shares of common stock sold in this offering. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of the date of this prospectus
supplement, the aggregate market value of our outstanding shares of common stock held by non-affiliates was approximately $24.7 million
based on 30,135,798 shares of common stock outstanding, of which 9,077,623 shares were held by affiliates, based on a price of $1.1750
per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on July 29, 2025. During the 12 calendar
months prior to and including the date hereof, we have not sold any securities pursuant to General Instruction&nbsp;I.B.6. of Form S-3.
Pursuant to General Instruction&nbsp;I.B.6&nbsp;of Form S-3, in no event will we sell securities in a public primary offering with a
value exceeding one-third of our public float in any 12-month period so long as our public float remains below $75.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. You should carefully consider all of the information set forth in this prospectus
supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement before deciding to
invest in our common stock. Please see &ldquo;<A HREF="#RMa_003">Risk Factors</A>&rdquo; on page S-13 of this prospectus supplement and
in our Annual Report on Form 10-K for the year ended December 31, 2024, which is incorporated by reference into this prospectus supplement
and the accompanying prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities being offered
by this prospectus supplement or the prospectus to which it relates, or determined if this prospectus supplement or the prospectus to
which it relates are truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter expects to deliver the shares to purchasers on or about July&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
    Managing Underwriter</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Craig-Hallum</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    date of this prospectus supplement is July&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
of Contents</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
Supplement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#RMa_001"><FONT STYLE="font-size: 10pt">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#RMa_002"><FONT STYLE="font-size: 10pt">PROSPECTUS
    SUPPLEMENT SUMMARY</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#RMa_003"><FONT STYLE="font-size: 10pt">RISK
    FACTORS</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#RMa_004"><FONT STYLE="font-size: 10pt">SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_001"><FONT STYLE="font-size: 10pt">USE
    OF PROCEEDS</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_002"><FONT STYLE="font-size: 10pt">DIVIDEND
    POLICY</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_003"><FONT STYLE="font-size: 10pt">DILUTION</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_004"><FONT STYLE="font-size: 10pt">MATERIAL
    U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS OF COMMON STOCK</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_005"><FONT STYLE="font-size: 10pt">UNDERWRITING</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-23</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_006"><FONT STYLE="font-size: 10pt">LEGAL
    MATTERS</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-28</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_007"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-28</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_008"><FONT STYLE="font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#ak_009"><FONT STYLE="font-size: 10pt">INCORPORATION
    OF CERTAIN INFORMATION BY REFERENCE</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-30</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="RMa_001"></A><FONT STYLE="font-size: 10pt; text-transform: none">ABOUT
THIS PROSPECTUS SUPPLEMENT</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is part of a registration statement that was filed with the Securities and Exchange Commission, or SEC, using a &ldquo;shelf&rdquo;
registration process and consists of two parts. The first part is this prospectus supplement, which describes the terms of this offering
of common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference
into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, dated August 25, 2023,
including the documents incorporated by reference therein, provides more general information. Generally, when we refer to &ldquo;this
prospectus&rdquo;, we are referring to both parts of this document combined. To the extent there is a conflict between the information
contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document
incorporated by reference that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely
on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another
document having a later date &mdash; for example, a document incorporated by reference in the accompanying prospectus &mdash; the statement
in the document having the later date modifies or supersedes the earlier statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States, we have not done anything that would permit this offering or possession or distribution of this
prospectus supplement and the accompanying prospectus in any jurisdiction where action for that purpose is required, other than in the
United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution
of this prospectus supplement and the accompanying prospectus outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompanying prospectus and any free writing prospectus may contain or incorporate by reference, industry,
statistical and market data from our own internal estimates and research as well as from industry and general publications and research,
surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained
from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe
that each of these studies and publications is reliable, we have not independently verified statistical, market and industry data from
third-party sources. While we believe our internal company research is reliable and the market definitions are appropriate, neither such
research nor these definitions have been verified by any independent source.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not, and the underwriter has not, authorized anyone to provide you with information different than or inconsistent with the information
contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus
that we may authorize for use in connection with this offering. We and the underwriter take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. We are not, and the underwriter is not, making an
offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing
in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and
the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate
only as of the date of those respective documents, regardless of the time of delivery of those respective documents. Our business, financial
condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying
prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing
prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You
should also read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement
entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this prospectus supplement to &ldquo;Dyadic,&rdquo; &ldquo;Dyadic Applied BioSolutions,&rdquo; &ldquo;the Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; or similar references refer to Dyadic International, Inc., d/b/a Dyadic Applied
BioSolutions, a Delaware corporation, and its subsidiaries on a consolidated basis, except where the context otherwise requires or as
otherwise indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the information incorporated herein by reference include trademarks, service marks and trade names owned by
us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement,
the accompanying prospectus or any related free writing prospectus are the property of their respective owners. Use or display by us
of trademarks, service marks or trade names owned by others is not intended to and does not imply a relationship between us and, or endorsement
or sponsorship by, the owners of the trademarks, service marks or trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="RMa_002"></A>PROSPECTUS
SUPPLEMENT SUMMARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference
into this prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before
deciding whether to invest in our common stock. For a more complete understanding of our company and this offering, you should read and
consider carefully the more detailed information included or incorporated by reference in this prospectus supplement, including the factors
described under the heading &ldquo;Risk Factors&rdquo; on page S-13 of this prospectus supplement and in our <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925009350/dyai20241231_10k.htm" STYLE="-sec-extract: exhibit">Annual
Report on Form 10-K</A> for the year ended December 31, 2024 filed with the SEC on March 26, 2025, which is incorporated by reference
into this prospectus supplement and the accompanying prospectus, as well as the information included in any free writing prospectus that
we may authorize for use in connection with this offering.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
International, Inc. is a biotechnology platform company headquartered in Jupiter, Florida, with operations in the U.S. and the Netherlands.
We aim to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences,
food and nutrition, and bio-industrial markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary platforms&mdash;Dapibus&trade; and C1&mdash;are designed for rapid, cost-effective, and flexible production of high-value
proteins, enabling partners to reduce development timelines and manufacturing costs. While Dyadic&rsquo;s primary focus is on non-therapeutic
applications, both platforms retain the capability to produce biologics, such as vaccines and therapeutic proteins, for external partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic&rsquo;s
mission is to accelerate access to essential proteins by advancing faster, more affordable, and more scalable biomanufacturing technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform
Capabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic&rsquo;s
Dapibus&trade; and C1 platforms are engineered microbial expression systems optimized for high-yield, low-cost, and scalable protein
production. Built on decades of industrial experience, these platforms support applications in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cell
    culture media (e.g., albumin, transferrin, fibroblast growth factor (&ldquo;FGF&rdquo;))</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagnostics
    and research reagents</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
    food ingredients (e.g., alpha-lactalbumin, caseins, lactoferrin)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustainable
    industrial enzymes (e.g., biomass and dairy enzymes)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
targeting high-value proteins in expanding non-pharmaceutical markets, Dyadic is building a commercial pipeline that aligns with global
trends in sustainability, animal-free manufacturing, and bio-based innovation. Simultaneously, we continue to explore partnering opportunities
for the use of our platforms in pharmaceutical development where appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dapibus&trade;
Protein Production Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
accelerate commercialization and reduce regulatory risk, Dyadic developed the Dapibus&trade; platform&mdash;a proprietary expression
system designed to produce high-value, non-animal proteins and enzymes for non-pharmaceutical markets including life sciences, food and
nutrition, and bio-industrial sectors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dapibus&trade;
is expected to enable faster development, lower production costs, and simplified regulatory pathways compared to therapeutic biologics,
which Dyadic believes will allow it to address growing demand for sustainable, functional ingredients across a range of industries. The
platform supports applications in bioprocessing, product formulation, diagnostics, and nutrition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
expects to commercialize multiple Dapibus&trade;-enabled products starting in 2025 through a combination of strategic partnerships and
internal manufacturing initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C1
Protein Production Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic&rsquo;s
proprietary C1 expression system is a patented, thermophilic fungal platform (<I>Thermothelomyces heterothallica</I> fungus) developed
for the cost-effective, large-scale production of proteins. Originally used to manufacture industrial enzymes, Dyadic has engineered
C1 into a high-yield, scalable platform for both biopharmaceutical and non-pharmaceutical applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the 2015 sale of its industrial enzyme business to Danisco USA (a DuPont subsidiary), Dyadic retained co-exclusive rights to the C1 platform
for human and animal pharmaceutical use, including the exclusive ability to sub-license C1 for human and animal pharmaceutical use (subject
to specific conditions). Danisco holds certain retained rights but is obligated to pay Dyadic royalties on any future pharmaceutical
commercialization. Dyadic may owe downstream royalties to Danisco or its licensors depending on specific patent usage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategic
Advantages and Applications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C1
is designed to address key bottlenecks in biologics manufacturing, offering potential advantages over legacy systems (e.g., CHO, E. coli,
and baculovirus), including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-yield
    expression of secreted proteins with minimal viscosity and simplified downstream purification.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avoidance
    of viral and endotoxin removal processes required by mammalian or bacterial systems.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proven
    scalability across lab and industrial fermenters, with demonstrated success producing correctly folded monoclonal antibodies (&ldquo;mAbs&rdquo;)
    comparable to CHO-derived equivalents.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C1
is being applied to develop a range of therapeutic and Life Science proteins, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutics:
                                            Vaccines, monoclonal and multi-specific antibodies.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life
                                            Sciences: Recombinant transferrin, albumin, fibroblast growth factor (FGF), DNase I, RNase
                                            inhibitors, reagents, and enzymes for diagnostics, cell culture, and biopharmaceutical manufacturing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
is engaged in multiple funded collaborations with pharmaceutical and biotech partners exploring C1&rsquo;s use in innovative vaccine
and therapeutic development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
believes the C1 platform&rsquo;s combination of scalability, speed, and efficiency makes it a compelling alternative for global bioproduction&mdash;supporting
near- and long-term opportunities in both commercial and strategic licensing partnerships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pipeline
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
is targeting high-growth, non-pharmaceutical markets with a focus on sustainable, animal-free proteins and enzymes. The Company&rsquo;s
Dapibus&trade; platform is engineered to deliver cost-effective, scalable production of high-quality proteins for use in food, nutrition,
wellness, and life science reagents. These markets are experiencing rapid growth driven by the demand for ethical, allergen-free, and
environmentally sustainable alternatives to animal-derived ingredients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dapibus&trade;
has already generated revenue from non-pharma applications and continues to advance through a focused pipeline of commercial-stage and
development-stage programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Food
and Nutrition Applications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
is applying Dapibus&trade; to develop and commercialize animal-free proteins for dairy alternatives and functional nutrition. Key programs
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dairy
                                            Enzyme Program: Under a development and exclusive license agreement signed in 2023, Dyadic
                                            received a $600,000 upfront payment and an additional $425,000 milestone payment in September
                                            2024 for achieving target yield. Commercial launch by partner expected in late 2025.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant
                                            Bovine Alpha-Lactalbumin: An improved production strain was developed in 2024. The product
                                            shows comparability to commercial benchmarks and is being actively sampled and characterized
                                            for use in dairy alternatives.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant
                                            Human Alpha-Lactalbumin: Development initiated in 2024 for applications in infant formula,
                                            medical nutrition, nutraceuticals, and pharmaceuticals.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant
                                            Human Lactoferrin: Cell line developed in 2024 for potential use in immune-supportive and
                                            antimicrobial products. Sampling expected to begin in the second half of 2025.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Casein
                                            Proteins: Four casein variants have been produced, and Dyadic is engaged in discussions with
                                            prospective commercial partners.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategic
Positioning</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic&rsquo;s
industrial-scale platform and track record in enzyme production position the Company to quickly advance from development to commercial
production. With a growing pipeline and multiple commercial collaborations, Dyadic is executing on a strategy expected to unlock near-term
revenue opportunities while building a diversified portfolio of non-animal proteins for global markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
&ldquo;Expected Launch Status&rdquo; for each of the products listed above is based on management estimates as of July 23, 2025, which
are subject to change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bio-Industrial
Applications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
seeks to leverage its Dapibus&trade; platform to develop and commercialize cost-effective, scalable enzyme solutions for bio-industrial
markets, supporting the global shift toward a more sustainable bioeconomy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
                                            Partnership with Fermbox Bio: In 2023, Dyadic partnered with Fermbox Bio to develop EN3ZYME,
                                            a proprietary enzyme cocktail launched in May 2024 for converting agri-residues into cellulosic
                                            sugars. Dyadic is expected to receive a 50/50 revenue profit share from commercial sales.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustainable
                                            Enzyme Portfolio: Dyadic is advancing enzymes applicable to multiple sectors including nutrition,
                                            pulp and paper, biogas, and biofuels. Sampling to potential commercial partners is ongoing.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyaluronidase
                                            Development: Initiated in 2024, this enzyme targets high-value markets including medical,
                                            cosmetic, and reproductive health. Sampling and commercial engagement are underway.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic&rsquo;s
bio-industrial initiatives aim to generate recurring revenue through strategic collaborations and licensing of high-performance enzymes
enabled by its proprietary production platforms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_004.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
&ldquo;Expected Launch Status&rdquo; for each of the products listed above is based on management estimates as of July 23, 2025, which
are subject to change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Life
Sciences</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
C1 platform is a robust and versatile gene expression system designed for the efficient production of high-value input proteins that
power the life sciences sector, such as cell culture media components, molecular biology reagents, and other critical bioprocessing inputs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_005.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
&ldquo;Expected Launch Status&rdquo; for each of the products listed above is based on management estimates as of July 23, 2025, which
are subject to change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cell
Culture Media</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
seeks to leverage its microbial platforms to produce high-value, animal-free growth media components for the biopharma and alternative
protein markets. Key developments include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant
                                            Serum Albumin: In partnership with Proliant Health and Biologicals, Dyadic is advancing toward
                                            a 2025 commercial launch of animal-free serum albumin for cell culture, diagnostics, and
                                            vaccine stabilization. Dyadic has received $1M in milestone payments to date, with additional
                                            payments and royalties tied to commercial success. Early data show strong comparability to
                                            industry standards and efficacy in cultured meat applications.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant
                                            Transferrin: Dyadic&#8217;s animal-free transferrin demonstrated equivalent performance to
                                            leading recombinant standards. Samples are being evaluated for research, diagnostics, and
                                            commercial bioprocessing.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant
                                            FGF: Critical for cell proliferation, Dyadic&#8217;s bovine FGF candidate has shown promising
                                            results in early testing for biopharma and cultivated meat applications. Sampling and validation
                                            are underway in 2025.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
                                            Co-Promotion: Dyadic has partnered with Biftek Co. to jointly promote growth media supplements
                                            for cell culture markets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"></P>









<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>DNA/RNA
Technologies</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
is expanding into molecular tools for diagnostics and life sciences, with several enzyme products in development:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNase-1:
                                            Completed development; production validation ongoing with a European Contract Development
                                            and Manufacturing Organization (&#8220;CDMO&#8221;). Research-grade product is expected
                                            by the end of 2025.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RNA/DNA
                                            Toolkit: Development underway for RNase Inhibitors, T7 RNA Polymerase, DNA Ligase, and Polymerases.
                                            Prototype enzymes have been produced, with optimization continuing into late 2025 and into
                                            2026.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pharmaceutical
Applications</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
Dyadic is focused on non-therapeutic markets, the C1 platform remains a validated solution for biopharmaceutical manufacturing and continues
to attract interest from pharma, CDMOs, academic institutions, and government agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C1
addresses key bottlenecks in biologics manufacturing&mdash;reducing cost, shortening development cycles, and enabling higher yields&mdash;positioning
it as a competitive alternative to CHO, yeast, and insect cell systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
opportunities include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recombinant
                                            vaccines and therapeutics (human and animal)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biobetters
                                            and biosimilars</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
                                            formulation and diagnostic reagents</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost-effective
                                            production of difficult-to-express proteins</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
continues to evaluate licensing, collaboration, and commercialization opportunities to unlock C1&rsquo;s full potential in the biologics
sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legacy
Biopharma Programs Support Strategic Growth and Platform Validation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic&rsquo;s
legacy pharmaceutical initiatives continue to drive platform validation, unlock non-dilutive funding, and support strategic collaborations
without diverting focus from its core commercial goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fully
Funded Global Health Collaborations</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gates
                                            Foundation: Awarded ~$3M grant (Nov 2024) to develop C1-based mAbs targeting RSV and malaria
                                            for underserved populations.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel
                                            Institute for Biological Research (IIBR): Ongoing collaboration to co-develop vaccines and
                                            biologics for emerging diseases and biothreats.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fondazione
                                            Biotecnopolo di Siena (FBS) / CEPI: $4.5M CEPI-funded project (March 2025), with Dyadic eligible
                                            for $2.4M, to accelerate development of C1-produced recombinant vaccines for global pandemic
                                            preparedness.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Advancing
C1 Vaccine Capabilities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ferritin
                                            Nanoparticle Vaccine Candidates (with ViroVax):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H5
                                            Avian Influenza: Demonstrated cross-protection in early trials; commercial interest in poultry,
                                            cattle, and human markets.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mpox:
                                            Early-stage preclinical development reinforcing C1&rsquo;s rapid response and low-cost manufacturing
                                            potential.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Diagnostics
and Animal Health Expansion</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C1-produced
                                            H5 antigens show strong neutralizing antibody response in poultry and promising cross-protection
                                            in cattle&#8212;with the potential to open new opportunities in animal health and diagnostics.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Strategic
Platform Partnerships</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cygnus
                                            Technologies&#174; (Maravai LifeSciences&#174;): Commercial launch of C1 Host Cell Protein
                                            (HCP) ELISA Kit to support C1/Dapibus&#8482; regulatory workflows.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rabian
                                            BV: Awaiting funding within Eurostars program for a rabies vaccine project using the C1 platform;
                                            Dyadic to receive equity in Rabian BV, certain milestone payments, and royalties on commercial
                                            sales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Peer-Reviewed
Validation and Clinical Progress</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature
                                            Communications (Mar 2024): C1-produced mAb showed protection against Omicron and Delta variants
                                            in non-human primates.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DYAI-100
                                            Vaccine Candidate: Phase 1 clinical trial met safety and immunogenicity endpoints. Future
                                            development paused to focus on emerging variants in collaboration with Rubic One Health (&#8220;Rubic&#8221;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
legacy programs provide critical third-party validation of the C1 platform&rsquo;s biopharmaceutical potential while generating non-dilutive
capital and enabling future commercial opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Licensing
and Strategic Collaborations</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rubic
One Health (South Africa)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, Dyadic expanded its license agreement with Rubic to include vaccines and therapeutic proteins for both human and animal health
in underserved African markets. The C1 platform tech transfer is complete. Dyadic is eligible to receive milestone payments, royalties,
and marketing rights under the agreement. In 2024, Rubic initiated development of several livestock vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phibro
Animal Health / Abic Biological Laboratories</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
entered an exclusive sublicense agreement with Abic, an affiliate of Phibro Animal Health Corporation, in February 2022. The agreement
was expanded in March 2024 to include additional vaccines and treatments for livestock diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
conducts internal and collaborative R&amp;D to advance its microbial platforms across both pharmaceutical and non-pharmaceutical applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>VTT
Technical Research Centre of Finland</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
2016, Dyadic has partnered with VTT, a leading European research institute, to enhance C1&rsquo;s safety, productivity, and efficiency.
VTT supports critical initiatives including glycoengineering, protease deletion, and therapeutic protein expression. Many projects at
VTT are co-funded by Dyadic&rsquo;s third-party collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
CRO and CDMO Partnerships</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
works with a global network of research providers and manufacturers, including 53Biologics (Spain), Fermbox Bio (India), and Eleszto
Genetika (Hungary). These partners support the Company&rsquo;s R&amp;D and scale-up activities across its platforms. While typically
structured as work-for-hire engagements, disruptions to these collaborations could impact timelines or development outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advancing
the Dapibus&trade; Platform for Scalable Commercial Applications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
continues to enhance the Dapibus&trade; platform to meet growing demand for cost-effective, scalable protein production across non-pharmaceutical
markets&mdash;including dairy, biofuels, biogas, biorefining, and alternative proteins. In collaboration with Eleszto Genetika and leading
contract research organizations, key initiatives include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engineering
                                            new Dapibus&#8482; strains tailored to specific industrial applications.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improving
                                            genetic tools to accelerate development and boost protein expression.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reducing
                                            background protease activity to increase yields and product quality.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optimizing
                                            fermentation and purification processes to lower COGS.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
                                            high-expression cell lines to support large-scale commercial production.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Demonstrating
C1&rsquo;s Biopharmaceutical Capabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
parallel, Dyadic continues to validate the C1 platform for biopharmaceutical applications with key partners such as VTT. Notable advancements
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            development of high-yield production strains of human and bovine serum albumin, vaccine antigens
                                            (i.e., SARS CoV-2 Spike HA, NA, Mpox), and a number of complex biologics (ferritin nanoparticle
                                            antigens, scFvs, mAbs, Fc-fusions).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VTT
                                            developed the initial C1 cell line used in the successfully completed DYAI-100 SARS-CoV-2
                                            vaccine Phase 1 clinical study.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mAbs
                                            produced in C1 showing comparable binding kinetics and glycosylation profiles to CHO cell-derived
                                            antibodies.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
                                            validation of neutralizing activity for C1-expressed antibodies and multi-specific biologics.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
efforts position Dyadic&rsquo;s platforms as versatile, low-cost solutions for both industrial and therapeutic protein markets, expanding
commercial potential across multiple verticals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Market Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the versatility of our robust portfolio of recombinant proteins that we expect to launch in the next two years, we believe that we are
well-positioned to pursue a combined total addressable market of approximately over $25B across life sciences, food and nutrition, and
bio industrial segments. The estimated total addressable market for our current recombinant solutions portfolio is comprised of opportunities
in the following areas:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Life
Sciences</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cell
Culture Media</I></B>: Approximately $5 billion global market. We define total addressable market as approximately $2B global revenue
opportunity for our recombinant solutions within the albumin, transferrin and growth factors markets. This was calculated using publicly
available third-party data to estimate the recombinant protein shares for these products within the global cell culture media market.
We will seek to serve the Cell Culture Media market, direct sales and OEM supply agreements for our recombinant cell culture media solutions,
such as transferrin and growth factors to third-party manufacturers, distributors, repackagers and strain/platform licensing agreements
key strategic partnerships with companies operating within the cell culture media space such as our commercial agreement with Proliant
Health and Biologics to produce and commercialize recombinant human albumin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Molecular
Biology Reagents</I></B>: Approximately $2 billion. We define total addressable market as the global revenue opportunity for our molecular
biology reagents and recombinant DNase solutions in life science research. This was calculated using publicly available third-party data
to estimate the recombinant protein shares for these products within the molecular biology reagent market. We will seek to serve the
molecular biology reagent market through strain/platform licensing agreements, direct sales and OEM supply agreements for our recombinant
molecular biology reagent solutions, such as DNASE-1 and others to third-party manufacturers, distributors, repackagers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Food
and Nutrition</U>: Approximately $11 billion. We define total addressable market as the global revenue opportunity for our recombinant
solutions within the dairy protein, alpha-lactalbumin and functional proteins and dairy enzymes markets. This was calculated using publicly
available third-party data to estimate the recombinant protein shares for these products within the Food and Nutritional market. We will
seek to serve the Food and Nutrition market through direct sales and OEM supply agreements for our non-animal dairy, research products
and other solutions to third-party manufacturers, distributors, repackagers and key strain/platform licensing agreements with strategic
companies operating within the Food and Nutrition segment, such as our commercialization agreement with Inzymes to produce non-animal
dairy enzymes markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bio-Industrial</U>:
Approximately $6 billion. We define total addressable market as the global revenue opportunity for our recombinant bio-industrial protein
and enzyme solutions within, biofuels pulp, paper, textiles, cosmetics solutions and other applications. This was calculated using publicly
available third-party data to estimate the recombinant protein shares for these products within the cellulosic Bio Industrial market.
We will seek to serve the Bio-Industrial market through direct sales and OEM supply agreements for our biomass processing and other solutions
to third-party manufacturers, distributors, repackagers and key strain/platform licensing agreements, with strategic companies operating
within the Bio-Industrial markets, such as our commercialization agreement with Fermbox Bio to produce cellulosic enzyme solutions for
biomass processing. We believe we can leverage our proprietary microbial platforms, C1 and Dapibus&trade;, as well as our growing portfolio
of high-value input proteins to target these markets. For additional information, see &ldquo;&mdash;Our Pipeline.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Platform
Strengths and Competitive Positioning</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic&rsquo;s
proprietary C1 and Dapibus&trade; platforms are designed to offer a scalable, cost-effective alternative to traditional protein production
systems across pharmaceutical and non-pharmaceutical applications. These platforms are engineered to produce vaccines, antibodies, enzymes,
and nutritional proteins with greater efficiency, shorter development timelines, and lower cost of goods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compared
to legacy expression systems, Dyadic&rsquo;s platforms offer the following potential advantages:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHO
                                            Cells (Mammalian): Industry standard for complex biologics but limited by long development
                                            cycles, high production costs, and complex purification requirements.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
                                            coli (Bacterial): Fast and inexpensive, but often produces insoluble proteins requiring refolding
                                            and generates pyrogenic contaminants, limiting use in biologics and precision food applications.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeast
                                            (e.g., Pichia pastoris): Lacks pyrogenic components and offers advanced genetic tools but
                                            can exhibit undesirable glycosylation and lower expression for certain targets.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insect
                                            Cells (Baculovirus): Used for vaccines and post-translational modifications but generally
                                            produce lower protein titers and require viral inactivation steps, adding time and cost.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trichoderma
                                            (Filamentous Fungi): Common in industrial enzyme production but limited by high protease
                                            activity and lower yields for non-native proteins.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
believes C1 and Dapibus&trade; combine the scalability of microbial systems with the productivity and versatility needed to serve diverse
end markets&mdash;positioning the Company as a next-generation platform provider in the global protein production landscape.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Commercialization Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
aim to accelerate access to essential proteins by turning our engineered strains into scalable revenue streams through:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Developing
                                            Our Engineered Strains</U>: Our C1 and Dapibus&#8482; platforms are scalable, flexible expression
                                            systems enabling high-yield, cost-effective and animal-free protein production that will
                                            lead to custom, high-performance microbial strains.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Monetization
                                            of Key Channels</U>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Strain
                                            Licensing</I>: Existing agreements, such as the License and Development Agreement with Proliant
                                            Biologicals, LLC d/b/a Proliant Health and Biologicals, provide licensing fees and royalties
                                            for our products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Strategic
                                            Partnerships</I>: Established strategic partnerships providing milestone payments (i.e.,
                                            Inzymes), generating revenue through collaboration and earning revenue through bulk supply
                                            sales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Direct
                                            Product Sales</I>: Direct-to-customer sales with third-party distributors and OEM channels
                                            for scalability.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Recurring
                                            Revenue</U>: Scalable revenue streams with increasing gross margin, shorter time-to-market
                                            products and embedding our products in manufacturing and supply chains.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in highly competitive and rapidly evolving sectors that include biotechnology, life sciences, food and nutrition, and industrial
bioprocessing. Our proprietary C1 and Dapibus&trade; microbial expression platforms are designed to offer cost-effective, scalable alternatives
to traditional protein production systems. While we believe our platforms provide unique advantages in terms of yield, speed, and versatility,
we face competition from both established and emerging players across our target markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
life sciences applications such as cell culture media components (e.g., albumin, transferrin, and growth factors) and molecular biology
reagents (e.g., DNase, RNase inhibitors, and polymerases), we compete with companies using mammalian (CHO), bacterial (E. coli), yeast,
and insect cell expression systems. These technologies are well established and supported by large, well-capitalized organizations, which
may enable them to commercialize competing products more rapidly or at greater scale than we can achieve initially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
food and nutrition markets&mdash;including functional dairy proteins and non-animal enzymes&mdash;competition is intensifying due to
the rise of precision fermentation and synthetic biology platforms. Several companies are actively developing recombinant proteins such
as caseins, whey components, and bioactive peptides for use in dairy alternatives, infant nutrition, and wellness applications. While
these markets present significant growth opportunities, many participants benefit from strong funding, strategic partnerships, and first-mover
advantages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the bio-industrial segment, we face competition from multinational enzyme producers and microbial fermentation companies developing enzymes
for applications such as biomass conversion, pulp and paper, and biofuels. Our strategy to collaborate with commercial partners, such
as Fermbox Bio, is intended to accelerate market entry and reduce capital intensity, but competitors may leverage larger sales networks
and existing customer relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we are not aware of other companies pursuing a directly comparable business model focused on commercializing a diversified portfolio
of non-animal recombinant proteins using fungal platforms optimized for non-therapeutic applications. However, given the pace of innovation
and increasing interest in sustainable bioproduction, it is possible that existing or new competitors could develop similar capabilities
or adopt comparable strategies in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Times New Roman, Times, Serif; padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
academic institutions, contract development and manufacturing organizations (CDMOs), and government-funded initiatives may contribute
to increased competition by advancing alternative production technologies or partnering with industry participants to bring new solutions
to market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the competitive landscape, we believe our platforms offer compelling differentiation due to their scalability, productivity, and cost
efficiency. However, there can be no assurance that we will be able to compete successfully against current or future competitors, or
that advancements by others will not render our technologies or product candidates obsolete or non-competitive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nasdaq
Deficiency Notice</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2025, the Company received a deficiency notice (the &ldquo;MVLS Notice&rdquo;) from the Nasdaq Listing Qualifications staff
(the &ldquo;Staff&rdquo;) of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) notifying the Company that for the last 30 consecutive
business days the Company&rsquo;s securities have not maintained the minimum Market Value of Listed Securities (&ldquo;MVLS&rdquo;) of
$35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2). The MVLS Notice has no immediate effect
on the listing of the Company&rsquo;s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(C),
the Company has 180 calendar days, or until December 20, 2025 (the &ldquo;MVLS Compliance Date&rdquo;), to regain compliance with the
minimum MVLS requirement by having the Company&rsquo;s MVLS close at $35 million or more for a minimum of 10 consecutive business days
before the MVLS Compliance Date (subject to the Staff&rsquo;s discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H)).
If the Company does not regain compliance by the MVLS Compliance Date, the Staff will provide written notification that the Company&rsquo;s
common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to
the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting
notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to actively monitor the MVLS of its common stock between now and the MVLS Compliance Date and, as appropriate, will evaluate
available options to resolve the deficiency and regain compliance with the minimum MVLS requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 17, 2025, the Company received a deficiency notice (the &ldquo;Minimum Bid Price Notice&rdquo;) from the Staff of Nasdaq notifying
the Company that for the last 30 consecutive business days the Company&rsquo;s common stock has not maintained the minimum bid price
of at least $1.00 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2) (the &ldquo;Minimum Bid
Price Requirement&rdquo;). The Minimum Bid Price Notice has no immediate effect on the listing of the Company&rsquo;s common stock on
the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until January
13, 2026 (the &ldquo;Minimum Bid Price Compliance Date&rdquo;), to regain compliance with the Minimum Bid Price Requirement by having
the Company&rsquo;s bid price close at $1 per share or more for a minimum of 10 consecutive business days before the Minimum Bid Price
Compliance Date (subject to the Staff&rsquo;s discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H)). If the Company
does not regain compliance by the Minimum Bid Price Compliance Date, the Company may be eligible for an additional 180-day period to
regain compliance, provided that on the Minimum Bid Price Compliance Date the Company meets the applicable market value of publicly held
shares requirement for continued listing and all other applicable standards for initial listing on the Nasdaq Capital Market (except
the bid price requirement) based on the Company&rsquo;s most recent public filings and market information and notifies Nasdaq of its
intent to cure this deficiency. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the
Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Minimum Bid Price
Compliance Date, the Staff will provide written notification that the Company&rsquo;s common stock is subject to delisting. At that time,
the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq
listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination
by Nasdaq to the panel, such appeal would be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to actively monitor the bid price of its common stock between now and the Minimum Bid Price Compliance Date and, as appropriate,
plans to evaluate available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>DBA
Name Change Update</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2025, we announced that, effective on August 1, 2025, we will be doing business as Dyadic Applied BioSolutions. This rebranding
initiative marks a strategic transition from a research-driven organization to a commercially focused enterprise. The new name and visual
identity better reflect the emphasis on delivering applied biotechnology solutions through our patented and proprietary C1 and Dapibus&trade;
gene expression platforms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
underscores our focus on commercializing high-value, non-therapeutic proteins in the life sciences, food, nutrition and industrial bioprocessing
sectors. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics, enabling faster time to
revenue, broader market reach, and long-term supply agreements. Our recent significant milestones across both food and nutrition as well
as fully funded legacy collaborations, such as with the Gates Foundation, underscore our strategic shift to revenue-focused bioprocessing
protein platforms from therapeutic and vaccine development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Information</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Delaware in September 2002, under the name &ldquo;Dyadic International, Inc.&rdquo; and recently announced on July
2, 2025, that, effective August 1, 2025, we will be doing business as Dyadic Applied BioSolutions. Our principal corporate offices are
located at 1044 North U.S. Highway One, Suite 201, Jupiter, FL 33477. Our telephone number is (561) 743-8333. Our website is www.dyadic.com.
Information accessed through our website is not incorporated into this prospectus supplement and is not a part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock Offered By Us</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    Price</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock Outstanding Immediately After This Offering</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds from this offering for working capital and general corporate purposes, such as product development,
    sales and marketing. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter
    Warrants</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the closing of this offering, we will issue as compensation to the underwriter, warrants to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock (5.0% of the aggregate number of shares of common stock sold in this offering)
    at an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, or the Underwriter Warrants. The Underwriter Warrants
    expire five years after the date of issuance. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    Capital Market Symbol</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DYAI</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our common stock involves a high degree of risk. See &ldquo;Risk Factors.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indication of Interest</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Joseph Hazelton, our President and Chief Operating Officer,
    has indicated his preliminary interest in purchasing approximately $25,000 of shares of our common stock in this offering at the
    public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriter
    may determine to sell more, fewer or no shares in this offering to Mr. Hazelton, or Mr. Hazelton may determine to purchase more,
    fewer or no shares in the offering. The underwriter will receive the same underwriting discount on any shares of common stock purchased
    by Mr. Hazelton as they will on any other shares sold to the public in this offering.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding immediately after this offering as shown above is based on 30,090,661 shares
of common stock outstanding as of March 31, 2025 and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,304,597</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of our common stock issuable upon the exercise of options outstanding as of March
                                            31, 2025, having a weighted-average exercise price of $2.85 per share;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">96,984
                                            shares of our common stock issuable upon the vesting of restricted stock units outstanding
                                            as of March 31, 2025; and</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,255,606</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of our common stock reserved for future issuance under our 2021 Equity Incentive Award
                                            Plan, or the 2021 Plan, as of March 31, 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding options or warrants after
March 31, 2025, including any shares of common stock issuable upon exercise of the Underwriter Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="RMa_003"></A><FONT STYLE="font-size: 10pt; text-transform: none">RISK
FACTORS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; contained in this prospectus supplement and any related
free writing prospectus, and discussed under the section titled &ldquo;Risk Factors&rdquo; contained in our most recent Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which
are incorporated by reference into this prospectus supplement and the accompanying prospectus in their entirety, together with other
information in this prospectus supplement, the accompany prospectus, the documents incorporated by reference herein and therein and any
free writing prospectus that we may authorize for use in connection with this offering. The risks described in these documents are not
the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive,
regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable
indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of
these risks occurs, our business, business prospects, financial condition, results of operations or cash flow could be seriously harmed.
This could cause the trading price of our securities to decline, resulting in a loss of all or part of your investment. Please also carefully
read the section below titled &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to this Offering and our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have in the past, and may in the future, be unable to comply with the listing standards of the Nasdaq Stock Market LLC, or Nasdaq. If
we fail to comply with listing standards in the future, our common stock may be delisted. Delisting could adversely affect the liquidity
of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital
to fund our operations and to continue to operate as a going concern would be substantially impaired.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on the Nasdaq Capital Market, which has minimum requirements that a company must meet in order to remain
listed. These requirements include maintaining a minimum MVLS of $35 million, which MVLS cannot fall below $35 million for a period of
more than 30 consecutive trading days, or the MVLS Requirement. On June 23, 2025, we received a deficiency notice from the Staff of Nasdaq,
notifying us that, for the last 30 consecutive business days, the Company&rsquo;s securities have not maintained the minimum MVLS of
$35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2). The MVLS Notice has no immediate effect
on the listing of the Company&rsquo;s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(C),
the Company has 180 calendar days, or until December 20, 2025, to regain compliance with the minimum MVLS requirement by having the Company&rsquo;s
MVLS close at $35 million or more for a minimum of 10 consecutive business days before the MVLS Compliance Date (subject to the Staff&rsquo;s
discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H)). On July 17, 2025, we received a separate deficiency notice
from the Staff of Nasdaq notifying the Company that for the last 30 consecutive business days the Company&rsquo;s securities have not
maintained the minimum bid price of at least $1 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2).
The Minimum Bid Price Notice has no immediate effect on the listing of the Company&rsquo;s common stock on the Nasdaq Capital Market.
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until January 13, 2026 to regain compliance
with the minimum bid price requirement by having the Company&rsquo;s bid price close at $1 per share or more for a minimum of 10 consecutive
business days before the Minimum Bid Price Compliance Date (subject to the Staff&rsquo;s discretion to extend this period under Nasdaq
Listing Rule 5810(c)(3)(H)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company does not regain compliance by the MVLS Compliance Date or the Minimum Bid Price Compliance Date, the Staff will provide written
notification that the Company&rsquo;s common stock is subject to delisting. At that time, the Company may appeal the delisting determination
to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that,
if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful.
In the event we fail to comply with listing standards in the future, and we do not regain compliance with the MVLS Requirement or the
Minimum Bid Price Requirement prior to the expiration of the applicable compliance period, unless Nasdaq exercises its discretion to
extend this period, our common stock may be subject to a delisting action by Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that our common stock is delisted from Nasdaq as a result of our failure to comply with the MVLS Requirement or the Minimum
Bid Price Requirement, as a result of Nasdaq not granting us an extension or the panel not granting us a favorable decision or due to
our failure to continue to comply with any other requirement for continued listing on Nasdaq, trading of our common stock could be conducted
in the over-the-counter market established for unlisted securities such as the OTCQX, the OTCQB, the OTCID Basic Market or the Pink Limited
Market, but there can be no assurance that our common stock will be eligible for trading on any such alternative market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if our common stock is delisted from Nasdaq, the liquidity of our common stock would be adversely affected, the market price of our common
stock could decrease, our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going
concern would be substantially impaired and transactions in our common stock could lose federal preemption of state securities laws.
Furthermore, there could also be a reduction in our coverage by securities analysts and the news media and broker-dealers may be deterred
from making a market in or otherwise seeking or generating interest in our common stock, which could cause the price of our common stock
to decline further. Moreover, delisting may also negatively affect our collaborators&rsquo;, vendors&rsquo;, suppliers&rsquo; and employees&rsquo;
confidence in us and employee morale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase shares of common stock in this offering, you will experience immediate and substantial dilution in your investment.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common
stock, you will suffer immediate and substantial dilution with respect to the net tangible book value of the common stock you purchase
in this offering. Based on the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and our net
tangible book value of $923,611, as of March 31, 2025, if you purchase shares of common stock in this offering,
you will suffer immediate and substantial dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share with respect to
the net tangible book value of the common stock. See the section entitled &ldquo;Dilution&rdquo; for a more detailed discussion of the
dilution you will incur if you purchase common stock in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will have broad discretion in the use of the net proceeds from this offering and could spend the proceeds in ways that do not improve
our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material
adverse effect on our business, impair or delay our ability to develop our product candidates, and cause the price of our common stock
to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your
sole source of gain</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock. We anticipate that we will retain our earnings, if any, for future growth
and therefore do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common stock
will provide a return to shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="RMa_004"></A><FONT STYLE="font-size: 10pt; text-transform: none">SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompany prospectus, the information incorporated by reference herein and therein and any free writing prospectus
that we may authorize for use in connection with this offering contain &ldquo;forward-looking statements&rdquo; within the meaning of
Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. These statements relate
to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors
that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements
expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our future results of operations and financial condition, expectations, business strategy and plans and
objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified
by words such as &lsquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;design,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; or the negative of these terms or other similar
expressions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements on our beliefs, assumptions and expectations of future performance, considering the information
currently available to us. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions,
including risks described in the section titled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus supplement and in our most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings
with the SEC, which are incorporated by reference into this prospectus supplement and the accompanying prospectus in their entirety,
together with other information in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein
and therein and any free writing prospectus that we may authorize for use in connection with this offering. These factors include, among
other things: (1) our history of net losses, (2) changes in global economic and market conditions; (3) our ability to generate the required
productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical
and non-pharmaceutical research and business plans and strategic initiatives; (4) our ability to retain and attract employees, consultants,
directors and advisors; (5) our ability to implement and successfully carry out Dyadic&rsquo;s and third parties&rsquo; research and
development efforts; (6) our ability to obtain new license and research agreements; (7) our ability to maintain existing access to, and/or
expand access to third-party contract research organizations and other service providers in order to carry out our research and development
projects and commercial activities for ourselves and third parties; (8) competition, including from alternative technologies, and reliance
on our key customers and collaborators; (9) our ability, and the ability of the contract research organizations and other third-party
service providers with whom we are currently working with or may work with in the future, to advance product candidates into, and successfully
complete, preclinical studies, non-clinical and clinical trials; (10) failure to commercialize our microbial protein production platforms
or our other technologies; (11) market and regulatory acceptance of our microbial protein production platforms and other technologies;
(12) the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological
materials owned by us and/or Danisco US, Inc. and VTT Technical Research Centre of Finland Ltd., and contract research organizations
that we engage with; (13) the speculative nature and illiquidity of equity securities received as consideration from sub-licenses; (14)
other factors discussed in the Company&rsquo;s publicly available filings, including information set forth under the caption &ldquo;Risk
Factors&rdquo; in our most recent Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information
currently available to us. These statements are only predictions based upon our current expectations and projections about future events.
There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially
from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we
operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure
and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks
emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors
on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements we may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events
and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation
to publicly update any forward-looking statements for any reason after the date of this prospectus supplement or to conform these statements
to actual results or to changes in our expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus supplement, the accompanying prospectus, the documents that we incorporate by reference herein and therein
and have filed as exhibits to the registration statement of which this prospectus supplement is a part, and any free writing prospectus
that we may authorize for use in connection with this offering with the understanding that our actual future results, levels of activity,
performance and achievements may be different from what we expect. We qualify all our forward-looking statements by these cautionary
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_001"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds we will receive from the sale of shares of our common stock that we are offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses
payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering for working capital and general corporate purposes, such as product development, sales
and marketing. In addition, we may use a portion of the net proceeds for potential acquisitions and other strategic transactions, although
we have no current plans, commitments or agreements to do so as of the date of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not determined the amount of net proceeds to be used specifically for the foregoing purposes. Accordingly, our management will have
broad discretion in the application of the net proceeds and investors will be relying upon the judgment of our management regarding the
application of these proceeds. We reserve the right to change the use of these proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
these uses, we intend to invest the proceeds of this offering in short-term, investment grade, interest-bearing securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_002"></A>DIVIDEND
POLICY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid dividends on our common stock, and currently do not plan to pay any cash dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_003"></A>DILUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net tangible book value as of March 31, 2025 was $923,611, or approximately $0.03 per share. Net tangible book value
is total assets minus the sum of liabilities and intangible assets. Net tangible book value per share is net tangible book value divided
by the total number of shares of common stock outstanding as of March 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
in net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock
in this public offering and the net tangible book value per share of our common stock immediately after completion of this public offering.
After giving effect to the sale of shares of our common stock in this offering at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted
net tangible book value as of March 31, 2025 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in net tangible
book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing stockholders and immediate dilution
in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors purchasing our
common stock in this offering at the public offering price. The following table illustrates this dilution on a per share basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Public offering price per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Net tangible book value per share as of March 31, 2025</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.03</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Increase in net tangible book value per share attributable to new investors
    purchasing shares of our common stock in this offering</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">As adjusted net tangible book value per share on March 31, 2025, after giving effect to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Dilution per share to new investors purchasing shares of our common stock
    in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above discussion and table are based on 30,090,661 shares of common stock outstanding as of March 31, 2025 and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,304,597</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of our common stock issuable upon the exercise of options outstanding as of March
                                            31, 2025, having a weighted-average exercise price of $2.85 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,984</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of our common stock issuable upon the vesting of restricted stock units outstanding
                                            as of March 31, 2025; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,255,606</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            shares of our common stock reserved for future issuance under the 2021 Plan as of March 31,
                                            2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that outstanding options are exercised or restricted stock unit awards vest, you will experience further dilution. In addition,
we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient
funds for our current or future operating plans. To the extent that additional capital is raised through the sale of our common stock,
or securities convertible into or exchangeable or exercisable for common stock, the issuance of these securities could result in further
dilution to investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_004"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS OF COMMON STOCK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the
purchase, ownership and disposition of our common stock acquired in this offering but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local,
or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code,
its legislative history, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative
pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect as of the date hereof. These authorities may
change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner
that could adversely affect a Non-U.S. Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding
the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding
the tax consequences of the purchase, ownership and disposition of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is limited to Non-U.S. Holders that acquire our common stock in this offering and hold our common stock as a &ldquo;capital
asset&rdquo; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address
all U.S. federal income tax consequences relevant to a Non-U.S. Holder&rsquo;s particular circumstances, including the impact of the
Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject
to special rules, including, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
                                            expatriates and former citizens or long-term residents of the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            subject to the alternative minimum tax;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            holding our common stock as part of a wash sale, constructive sale, hedge, straddle, or other
                                            risk reduction strategy or as part of a conversion transaction or other integrated investment;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            subject to special tax accounting rules as a result of any item of gross income with respect
                                            to our common stock being taken into account in an applicable financial statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
                                            insurance companies and other financial institutions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers,
                                            dealers, or traders in securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;controlled
                                            foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations
                                            that accumulate earnings to avoid U.S. federal income tax;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
                                            or other entities or arrangements treated as partnerships for U.S. federal income tax purposes
                                            (and investors therein) or other entities or arrangements that are pass-through or disregarded
                                            entities for U.S. federal income tax purposes or persons that hold their common stock through
                                            such partnerships or other entities or arrangements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
                                            organizations or governmental organizations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            deemed to sell our common stock under the constructive sale provisions of the Code;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            who hold or receive our common stock pursuant to the exercise of any employee stock option
                                            or otherwise as compensation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            that own or have owned, or are deemed to own or have owned, more than 5% of our common stock
                                            (except to the extent specifically set forth below);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated
                                            investment companies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real
                                            estate investment trusts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-qualified
                                            retirement plans; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;qualified
                                            foreign pension funds&#8221; as defined in Section 897(l)(2) of the Code and entities all
                                            of the interests of which are held by qualified foreign pension funds.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity (or arrangement) treated as a partnership or a pass-through entity for U.S. federal income tax purposes holds our common stock,
the tax treatment of a partner or beneficial owner of the entity will depend on the status of the partner or beneficial owner, the status
and activities of the entity and certain determinations made at the partner or beneficial owner level. Accordingly, entities treated
as partnerships or pass-through entities for U.S. federal income tax purposes holding our common stock and the partners or beneficial
owners in such entities should consult their tax advisors regarding the U.S. federal income tax consequences to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definition
of a Non-U.S. Holder</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this discussion, a &ldquo;Non-U.S. Holder&rdquo; is a beneficial owner of our common stock that is not, for U.S. federal
income tax purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            individual who is a citizen or resident of the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            corporation or other entity treated as a corporation for U.S. federal income tax purposes
                                            created or organized in or under the laws of the United States, any state thereof or the
                                            District of Columbia;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            estate, the income of which is subject to U.S. federal income taxation regardless of its
                                            source; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            trust if it (1) is subject to the primary supervision of a court within the United States
                                            and one or more U.S. persons have the authority to control all substantial decisions of the
                                            trust, or (2) has a valid election in effect under applicable U.S. Treasury regulations to
                                            be treated as a U.S. person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Distributions</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in the section entitled &ldquo;Dividend Policy&rdquo; above, we currently do not plan to pay any cash distributions in the
foreseeable future. However, if we do make distributions of cash or other property on our common stock, such distributions will constitute
dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined
under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess amounts
will not be treated as dividends for U.S. federal income tax purposes. Rather, the excess will first constitute a return of capital and
be applied against and reduce a Non-U.S. Holder&rsquo;s adjusted tax basis in its common stock, but not below zero. Any remaining excess
will be treated as capital gain and will be treated as described below under &ldquo;&mdash;Gain on Disposition of Our Common Stock.&rdquo;
Any such distributions will also be subject to the discussions below under &ldquo;&mdash;Information Reporting Requirements and Backup
Withholding&rdquo; and &ldquo;&mdash;Additional Withholding Tax on Payments Made to Foreign Accounts.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below with respect to effectively connected dividends and subject to the discussions below of backup withholding and Sections
1471 to 1474 of the Code (such Sections and related Treasury Regulations commonly referred to as the Foreign Account Tax Compliance Act,
or FATCA), dividends paid to a Non-U.S. Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of
the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes
a valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the lower treaty rate). If a Non-U.S.
Holder holds the stock through a financial institution or other intermediary, the Non-U.S. Holder will be required to provide appropriate
documentation to the intermediary, which then will be required to provide appropriate documentation to the applicable withholding agent,
either directly or through other intermediaries. A Non-U.S. Holder that does not timely furnish the required documentation, but that
qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund
with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income
tax treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within
the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment or a
fixed base in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding
tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI,
certifying that the dividends are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within the United
States. Any such effectively connected dividends will be subject to U.S. federal income tax generally in the same manner as if the Non-U.S.
Holder were a U.S. person and be subject to U.S. federal income tax on a net income basis at the regular graduated U.S. federal income
tax rates. A Non-U.S. Holder that is a corporation may also be subject to a branch profits tax at a rate of 30% (or such lower rate specified
by an applicable income tax treaty) on its effectively connected earnings and profits for the taxable year that are attributable to such
dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that
may provide for different rules or rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Gain
on Disposition of Our Common Stock</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussions below regarding FATCA and backup withholding (<I>see </I>&ldquo;&mdash;Information Reporting Requirements and Backup
Withholding&rdquo; and &ldquo;&mdash;Additional Withholding Tax on Payments Made to Foreign Accounts&rdquo;), a Non-U.S. Holder generally
will not be subject to U.S. federal income tax or withholding tax on any gain realized upon the sale or other taxable disposition of
our common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business
                                            within the United States (and, if required by an applicable income tax treaty, the Non-U.S.
                                            Holder maintains a permanent establishment or a fixed base in the United States to which
                                            such gain is attributable);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            gain is recognized by a Non-U.S. Holder that is a nonresident alien individual present in
                                            the United States for 183 days or more during the taxable year of the disposition and certain
                                            other requirements are met; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            common stock constitutes a United States real property interest, or USRPI, as defined under
                                            Section 897I(1) of the Code, by reason of our status as a United States real property holding
                                            corporation, or USRPHC, as defined under Section 897I(2) of the Code, for U.S. federal income
                                            tax purposes, at any time within the shorter of the five-year period preceding such sale
                                            or other taxable disposition or the Non-U.S. Holder&#8217;s holding period for the applicable
                                            common stock, and certain other conditions are met.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the first bullet point above generally will be subject to U.S. federal income tax in the same manner as if the Non-U.S.
Holder were a U.S. person and be taxed on the net gain derived from the sale or other taxable disposition under regular graduated U.S.
federal income tax rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such
lower rate specified by an applicable income tax treaty) on a portion of its effectively connected earnings and profits for the taxable
year that are attributable to such gain, as adjusted for certain items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified
by an applicable income tax treaty), on the net gain derived from the disposition, which may be offset by U.S. source capital losses
of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has
timely filed U.S. federal income tax returns with respect to such losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the third bullet point above, we believe that we have not been and we are not, and do not anticipate becoming, a USRPHC. Generally,
a domestic corporation is a USRPHC if the fair market value of its USRPIs equals or exceeds 50% of the aggregate fair market value of
its worldwide real property interests and its other assets used or held for use in a trade or business. Even if we are treated as a USRPHC,
gain realized by a Non-U.S. Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1)
the Non-U.S. Holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter
of (i) the five-year period preceding the disposition or (ii) the Non-U.S. Holder&rsquo;s holding period, and (2) our common stock is
regularly traded on an established securities market. If the above exception does not apply, such Non-U.S. Holder generally will be taxed
on its net gain derived from the disposition at the U.S. federal income tax rates applicable to United States persons (as defined in
the Code). In addition, a buyer of our common stock from such Non-U.S. Holder may be required to withhold U.S. federal income tax at
a rate of 15% of the amount realized upon such disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
Holders should consult their tax advisors regarding the application of the above to their particular situation, including the potential
application of any available income tax treaty that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Information
Reporting Requirements and Backup Withholding</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
we must report information to the IRS with respect to any dividends we pay on our common stock (even if the payments are exempt from
withholding), including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld.
A similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties or certain other agreements, the
IRS may make its reports available to tax authorities in the recipient&rsquo;s country of residence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid by us (or our paying agents) to a Non-U.S. Holder may also be subject to U.S. backup withholding. U.S. backup withholding generally
will not apply to a Non-U.S. Holder who provides a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E, or IRS Form W-ECI, or otherwise
establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the payor has actual knowledge, or reason to
know, that the holder is a U.S. person who is not an exempt recipient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock effected
by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and such requirements may be avoided if
the holder provides a properly executed IRS Form W-8BEN or IRS Form W-8BEN-E or otherwise meets documentary evidence requirements for
establishing non-U.S. person status or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding
requirements will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United
States through a non-U.S. office of a non-U.S. broker. Information reporting and backup withholding requirements may, however, apply
to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person.
For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner
similar to U.S. brokers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a Non-U.S. Holder&rsquo;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
Holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Additional
Withholding Tax on Payments Made to Foreign Accounts</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal withholding taxes may be imposed under FATCA on certain types of payments made to non-U.S. financial institutions and certain
other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends, or, subject to the proposed Treasury Regulations
discussed below, gross proceeds from the sale or other disposition of, our common stock paid to a &ldquo;foreign financial institution&rdquo;
(as defined by the Code to include, in addition to banks and traditional financial institutions, entities such as investment funds and
certain holding companies) or a &ldquo;non-financial foreign entity&rdquo; (as defined in the Code), unless (1) the foreign financial
institution satisfies certain diligence, reporting and withholding requirements, (2) the non-financial foreign entity either certifies
it does not have any &ldquo;substantial United States owners&rdquo; (as defined in the Code) or furnishes identifying information regarding
each substantial United States owner, or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for
an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence, reporting and withholding
requirements in (1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that
it undertake to identify accounts held by certain &ldquo;specified United States persons&rdquo; or &ldquo;United States-owned foreign
entities&rdquo; (each as defined in the Code), annually report certain information about such accounts and withhold 30% on certain payments
to non-compliant foreign financial institutions and certain other account holders. Accordingly, the entity through which our common stock
is held will affect the determination of whether such withholding is required. Foreign financial institutions located in jurisdictions
that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on
our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition
of stock on or after January 1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely.
Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FATCA withholding tax will apply to all withholdable payments without regard to whether the beneficial owner of the payment would otherwise
be entitled to an exemption from imposition of withholding tax pursuant to an applicable tax treaty with the United States or U.S. domestic
law. Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their
investment in our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
U.S. FEDERAL INCOME TAX DISCUSSION SET FORTH ABOVE IS INCLUDED FOR GENERAL INFORMATION ONLY AND MAY NOT BE APPLICABLE DEPENDING UPON
A HOLDER&rsquo;S PARTICULAR SITUATION. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL
INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON
STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR
UNDER ANY APPLICABLE INCOME TAX TREATY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_005"></A>UNDERWRITING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering the shares of common stock described in this prospectus supplement and the accompanying prospectus through the underwriter
listed below. Craig-Hallum Capital Group, LLC is acting as the sole managing underwriter of this offering. The underwriter named below
has agreed to buy, subject to the terms of the underwriting agreement, the number of shares of common stock listed opposite its name
below. The underwriter is committed to purchase and pay for all of the shares if any are purchased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 80%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriter</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 16%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of Shares </B></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Craig-Hallum
    Capital Group LLC</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter has advised us that it proposes to offer the shares of common stock to the public at a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share. The underwriter proposes to offer the shares of common stock to certain dealers at the same price less a concession of not more
than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the offering, these figures may be changed by
the underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares sold in this offering are expected to be ready for delivery on or about July&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, against
payment in immediately available funds. The underwriter may reject all or part of any order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
Hazelton, our President and Chief Operating Officer, has indicated his preliminary interest in purchasing approximately $25,000 of shares
of our common stock in this offering at the public offering price. However, because indications of interest are not binding agreements
or commitments to purchase, the underwriter may determine to sell more, fewer or no shares in this offering to Mr. Hazelton, or Mr. Hazelton
may determine to purchase more, fewer or no shares in the offering. The underwriter will receive the same underwriting discount on any
shares of common stock purchased by Mr. Hazelton as they will on any other shares sold to the public in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the underwriting discounts that we will pay to the underwriter. In addition to the underwriting discount, we have agreed to pay up to $75,000 of the
fees and expenses of the underwriter, which may include the fees and expenses of counsel to the underwriter. The fees and expenses of
the underwriter that we have agreed to reimburse are not included in the underwriting discounts set forth in the table below. The underwriting
discount and reimbursable expenses the underwriter will receive were determined through arms&rsquo; length negotiations between us and
the underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1pt solid"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per
    Share</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Price
    to the public:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting
    discount to be paid by us</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds,
    before expenses, to us:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses of this offering, excluding underwriting discounts, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. This includes $75,000 of the
fees and expenses of the underwriter. These expenses are payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have agreed to indemnify the underwriter against certain liabilities, including civil liabilities under the Securities Act or to
contribute to payments that the underwriter may be required to make in respect of those liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Purchase
of Private Underwriter&rsquo;s Warrant</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to, upon the closing of this offering, issue to the underwriter or the underwriter&rsquo;s designee(s) to purchase a number of shares of common stock equal
to 5% of the total number of shares of common stock sold in this offering. The underwriter&rsquo;s warrant will be exercisable at 115%
of the public offering price and may be exercised on a cashless basis. The underwriter&rsquo;s warrant is exercisable at any time and
from time to time, in whole or in part, beginning 180 days after the closing of this offering and ending on the five-year anniversary
of the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter&rsquo;s warrant and the shares of common stock underlying the underwriter&rsquo;s warrant will be deemed compensation by
the Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;), and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)
of FINRA. The underwriter, or permitted assignees under such rule, may not sell, transfer, assign, pledge, or hypothecate the underwriter&rsquo;s
warrant or the securities underlying the underwriter&rsquo;s warrant, nor will the underwriter engage in any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the underwriter&rsquo;s warrant or the underlying
shares for a period of 180 days from the closing of this offering. Additionally, the underwriter&rsquo;s warrant may not be sold transferred,
assigned, pledged, or hypothecated for a 180-day period following the closing of this offering except to any underwriter and selected
dealer participating in this offering and their bona fide officers or partners. The underwriter&rsquo;s warrant will provide for adjustment
in the number and price of the underwriter&rsquo;s warrant and the shares of common stock underlying such underwriter&rsquo;s warrant
in the event of a recapitalization, merger, stock split or other structural transaction. We have granted the underwriter and its designees
certain registration rights relating to these securities. The underwriter and its designees may not exercise their &ldquo;piggy-back&rdquo;
registration rights seven years following the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">No
Sales of Similar Securities</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limited exceptions, we and each of our directors and executive officers, and each beneficial owner of 10% or more of our outstanding
common stock (each, a &ldquo;10% Holder&rdquo;) have agreed not to offer, sell, agree to sell, directly or indirectly, or otherwise dispose
of any shares of common stock or any securities convertible into or exchangeable for shares of common stock for a period of 90 days after
the date of this prospectus supplement. The lock-up agreements that our directors, executive officers, and 10% Holders have entered into
and the Company lock-up pursuant to the underwriting agreement provide limited exceptions and their restrictions may be waived at any
time by the underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Price
Stabilization, Short Positions and Penalty Bids</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
facilitate this offering, the underwriter may engage in transactions that stabilize, maintain or otherwise affect the price of our common
stock during and after the offering. Specifically, the underwriter may over-allot or otherwise create a short position in our common
stock for its own account by selling more shares of common stock than we have sold to the underwriter. Because the offering does not
include an over-allotment option, the underwriter would have to close out any short position by purchasing shares in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the underwriter may stabilize or maintain the price of our common stock by bidding for or purchasing shares in the open market
and may impose penalty bids. If penalty bids are imposed, selling concessions allowed to broker-dealers participating in this offering
are reclaimed if shares previously distributed in this offering are repurchased, whether in connection with stabilization transactions
or otherwise. The effect of these transactions may be to stabilize or maintain the market price of our common stock at a level above
that which might otherwise prevail in the open market. The imposition of a penalty bid may also affect the price of our common stock
to the extent that it discourages resales of our common stock. The magnitude or effect of any stabilization or other transactions is
uncertain. These transactions may be effected on Nasdaq or otherwise and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriter may also engage in passive market making transactions in our common stock on Nasdaq. Passive
market making consists of displaying bids on Nasdaq by the prices of independent market makers and effecting purchases limited by those
prices in response to order flow. Rule 103 of Regulation M promulgated by the SEC limits the amount of net purchases that each passive
market maker may make and the displayed size of each bid. Passive market making may stabilize the market price of our common stock at
a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions described
above may have on the price of our common stock. In addition, neither we nor the underwriter make any representation that the underwriter
will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Affiliations</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter and its affiliates are full-service financial institutions engaged in various activities, which may include securities trading,
commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing
and brokerage activities. The underwriter may in the future engage in investment banking and other commercial dealings in the ordinary
course of business with us or our affiliates. The underwriter may in the future receive customary fees and commissions for these transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of its various business activities, the underwriter and its affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for
their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or
instruments of the issuer. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent
research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long
and/or short positions in such securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Electronic
Offer, Sale and Distribution</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriter or certain of the securities dealers may distribute prospectuses by electronic means,
such as e-mail. In addition, the underwriter may facilitate Internet distribution for this offering to certain of its Internet subscription
customers. The underwriter may allocate a limited number of shares for sale to its online brokerage customers. An electronic prospectus
is available on the Internet websites maintained by any such underwriter. Other than the prospectus in electronic format, the information
on the websites of the underwriter is not part of this prospectus supplement or the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Selling
Restrictions</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered
by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus
supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements
in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances
that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus
supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution
of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any
securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>European
Economic Area.</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to each Member State of the European Economic Area (each, a &ldquo;Relevant State&rdquo;), no securities have been offered or
will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to
the securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant
State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that securities
may be offered to the public in that Relevant State at any time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any legal entity which is a qualified investor as defined under Article 2 of the Prospectus
                                            Regulation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            fewer than 150 natural or legal persons (other than qualified investors as defined under
                                            Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representative
                                            for any such offer; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other circumstances falling within Article 1(4) of the Prospectus Regulation,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>provided</I>
that no such offer of securities shall require us or any of the representative to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this provision, the expression an &ldquo;offer to the public&rdquo; in relation to any securities in any Relevant State
means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered
so as to enable an investor to decide to purchase or subscribe for any securities, and the expression &ldquo;Prospectus Regulation&rdquo;
means Regulation (EU) 2017/1129, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Kingdom.</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
securities have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication
of a prospectus in relation to the securities which has been approved by the Financial Conduct Authority, except that the securities
may be offered to the public in the United Kingdom at any time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus
                                            Regulation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            fewer than 150 natural or legal persons (other than qualified investors as defined under
                                            Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the
                                            representative for any such offer; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other circumstances falling within Section 86 of the Financial Services and Markets Act
                                            2000 (the &#8220;FMSA&#8221;),</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>provided</I>
that no such offer of the securities shall require us or any representative to publish a prospectus pursuant to Section 85 of the FSMA
or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression
an &ldquo;offer to the public&rdquo; in relation to the securities in the United Kingdom means the communication in any form and by any
means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase
or subscribe for any securities and the expression &ldquo;UK Prospectus Regulation&rdquo; means Regulation (EU) 2017/1129 as it forms
part of domestic law by virtue of the European Union (Withdrawal) Act 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada.</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriter is not required to comply with the
disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Switzerland.</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the &ldquo;SIX&rdquo;) or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses
under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland.
Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed
or otherwise made publicly available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this document nor any other offering or marketing material relating to the offering, or the shares have been or will be filed with or
approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be
supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of shares has not been and will not be authorized
under the Swiss Federal Act on Collective Investment Schemes (&ldquo;CISA&rdquo;). Accordingly, no public distribution, offering or advertising,
as defined in CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA, its
implementing ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers of
interests in collective investment schemes under CISA does not extend to acquirers of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Australia.</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission (&ldquo;ASIC&rdquo;), in relation to the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations
Act 2001 (the &ldquo;Corporations Act&rdquo;), and does not purport to include the information required for a prospectus, product disclosure
statement or other disclosure document under the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
offer in Australia of the shares may only be made to persons (the &ldquo;Exempt Investors&rdquo;) who are &ldquo;sophisticated investors&rdquo;
(within the meaning of section 708(8) of the Corporations Act), &ldquo;professional investors&rdquo; (within the meaning of section 708(11)
of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it
is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date
of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would
not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure
document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement contains general information only and does not take account of the investment objectives, financial situation or
particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making
an investment decision, investors need to consider whether the information in this prospectus supplement is appropriate to their needs,
objectives and circumstances, and, if necessary, seek expert advice on those matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_006"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered by this prospectus supplement and the accompanying prospectus will be passed upon for
us by White &amp; Case LLP, New York, New York. Faegre Drinker Biddle &amp; Reath LLP is counsel for the underwriter in connection with
this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_007"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The financial statements incorporated in this Prospectus by reference to the Annual Report on
Form 10-K for the year ended December 31, 2024 have been so incorporated in reliance on the report of Crowe LLP, independent registered
public accounting firm, given on the authority of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_008"></A>WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus are part of the registration statement on Form S-3 we filed with the SEC under
the Securities Act and does not contain all the information set forth or incorporated by reference in the registration statement. Whenever
a reference is made in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents,
the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits
to the reports or other documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a copy
of such contract, agreement or other document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy
statements and other information with the SEC. Our SEC filings are available for free to the public over the Internet at the SEC&rsquo;s
website at http://www.sec.gov. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including
any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of
the Exchange Act can also be accessed free of charge on the Investor section of our website. These filings will be available as soon
as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website address is http://dyadic.com/investors.
Information contained on or accessible through our website is not a part of this prospectus supplement and is not incorporated by reference
herein, and the inclusion of our website address in this prospectus supplement is an inactive textual reference only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ak_009"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to
be part of this prospectus supplement and the accompanying prospectus. Information in this prospectus supplement supersedes information
incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement, while information that we file
later with the SEC will automatically update and supersede the information in this prospectus supplement and the accompanying prospectus.
We incorporate by reference into this prospectus supplement, the accompanying prospectus and the registration statement of which this
prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No. 001-32513):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925009350/dyai20241231_10k.htm" STYLE="-sec-extract: exhibit">Form
                                            10-K for the year ended December 31, 2024, filed with the SEC on March 26, 2025</A>&#894;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925016866/dyai20250331_10q.htm" STYLE="-sec-extract: exhibit">Form
                                            10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025</A>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925013546/dyai20250416_8k.htm" STYLE="-sec-extract: exhibit">April
                                            29, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925014571/dyai20250504_8k.htm" STYLE="-sec-extract: exhibit">May
                                            5, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925019177/dyai20250602_8k.htm" STYLE="-sec-extract: exhibit">June
                                            2, 2025</A> (excluding the information furnished pursuant to Item 7.01 and the related exhibits
                                            furnished pursuant to Item 9.01), <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925021169/dyai20250605_8k.htm" STYLE="-sec-extract: exhibit">June
                                            24, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774925021420/dyai20250626_8k.htm" STYLE="-sec-extract: exhibit">June
                                            27, 2025</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000164117225020728/form8-k.htm" STYLE="-sec-extract: exhibit">July
                                            23, 2025</A> (the first Form 8-K on such filing date); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            description of our common stock set forth in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000121380919000013/form8anasdaquplisting.htm" STYLE="-sec-extract: exhibit">Form
                                            8-A, filed with the SEC on April 12, 2019</A>, <FONT STYLE="background-color: white">as updated
                                            by <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000121380920000018/exhibit42descriptionof.htm" STYLE="-sec-extract: exhibit">Exhibit
                                            4.2</A> to our Annual Report on Form 10-K for the fiscal year ended December 31,</FONT> 2024<FONT STYLE="background-color: white">,</FONT>
                                            including any amendments thereto or reports filed for the purposes of updating this description.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
filings filed by us pursuant to the Exchange Act after the date of the initial filing of the registration statement of which this prospectus
supplement and the accompanying prospectus are a part, effective upon filing, shall be deemed to be incorporated by reference into this
prospectus supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits
filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, until we file a post-effective amendment that indicates the termination of
the offering of the securities made by this prospectus supplement and the accompanying prospectus and will become a part of this prospectus
supplement and the accompanying prospectus from the date that such documents are filed with the SEC. Information in such future filings
updates and supplements the information provided in this prospectus supplement and the accompanying prospectus. Any statements in any
such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the
SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify
or replace such earlier statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information provided in and incorporated by reference into this prospectus supplement, the accompanying prospectus,
and any free writing prospectus that we may authorize for use in connection with this offering. We have not authorized anyone else to
provide you with different information. You should not assume that the information in this prospectus supplement, the accompanying prospectus,
the information incorporated by reference herein and therein and any free writing prospectus that we may authorize for use in connection
with this offering is accurate as of any date other than the date on the front cover of these documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can request a copy of any or all the reports or documents that have been incorporated by reference in this prospectus supplement (other
than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus supplement),
at no cost, by writing or telephoning us at the following address or telephone number.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
International, Inc., d/b/a/ Dyadic Applied BioSolutions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1044
North U.S. Highway One, Suite 201</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
Florida, 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(561)
743-8333</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DYADIC
INTERNATIONAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$50,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, from time to time, offer and sell up to $50,000,000&nbsp;of the securities described in this prospectus at prices and on terms described
in one or more supplements to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus describes some of the general terms that may apply to an offering of our securities. We will provide the specific terms of
these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses
to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also
add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus
supplement and any related free writing prospectus, as well as the documents incorporated by reference, before buying any of the securities
being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
may be sold by us to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional
information on the methods of sale, you should refer to the section titled &ldquo;Plan of Distribution&rdquo; in this prospectus and
in the applicable prospectus supplement. If any underwriters are involved in the sale of any securities with respect to which this prospectus
is being delivered, the names of such underwriters and any applicable discounts or commissions and options to purchase additional securities
will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from
such sale will also be set forth in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the trading symbol &ldquo;DY<FONT STYLE="background-color: white">AI.&rdquo;
On August 8, 2023, the closing price of our common stock was $1.73&nbsp;per</FONT> share. The applicable prospectus supplement will contain
information, where applicable, as to other listings, if any, on The Nasdaq Capital Market or other securities exchange of the securities
covered by the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should carefully read this prospectus and&nbsp;any applicable prospectus supplement relating to any specific offering of securities,
and all information incorporated by reference herein and therein prior to making an investment decision.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. These risks are discussed in this prospectus under &ldquo;Risk Factors</B>&rdquo; <B>beginning
on page 3 and in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q incorporated by reference into this
prospectus, the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with
a specific offering, and under similar headings in the other documents that are incorporated by reference into this
prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="toc_01"></A><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#RMa_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="RMa_005"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, using a
&ldquo;shelf&rdquo; registration process under the Securities Act of 1933, as amended, or the Securities Act. Under this prospectus,
we may sell the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $50,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement to this prospectus that
will contain more specific information about the terms of that offering. We may also authorize one or more free writing prospectuses
to be provided to you that may contain material information relating to these offerings. We may also add, update or change in a prospectus
supplement or free writing prospectus any of the information contained in this prospectus or in the documents we have incorporated by
reference into this prospectus. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus
and the documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material
information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement
and any related free writing prospectus, together with the additional information described under &ldquo;Where You Can Find More Information,&rdquo;
before buying any of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized anyone to provide you with any information other than contained in, or incorporated by reference into, this prospectus
and the applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for
use in connection with a specific offering. We take no responsibility for, and can provide no assurance as to the reliability of, any
other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances
and in jurisdictions where it is lawful to do so. You should not assume that the information contained in or incorporated by reference
in this prospectus or any prospectus supplement or in any such free writing prospectus is accurate as of any date other than their respective
dates. Our business, financial condition, results of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States, we have not done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform
yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus outside of the United
States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All&nbsp;the summaries are qualified in their entirety by the actual documents. Copies of
some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration
statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section titled
&ldquo;Where You Can Find More Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference,
industry, statistical and market data from our own internal estimates and research as well as from industry and general publications
and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have
been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
While we believe that each of these studies and publications is reliable, we have not independently verified statistical, market and
industry data from third-party sources. While we believe our internal company research is reliable and the market definitions are appropriate,
neither such research nor these definitions have been verified by any independent source.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context indicates otherwise, as used in this prospectus, the terms &ldquo;Dyadic,&rdquo; &ldquo;Dyadic International, Inc.&rdquo;
&ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Dyadic International, Inc. and, where appropriate,
its subsidiaries on a consolidated basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other
companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus
supplement or any related free writing prospectus are the property of their respective owners. Use or display by us of trademarks, service
marks or trade names owned by others is not intended to and does not imply a relationship between us and, or endorsement or sponsorship
by, the owners of the trademarks, service marks or trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="RMa_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary provides an overview of selected information contained elsewhere or incorporated by reference into this prospectus and does not
contain all the information you should consider before investing in our securities. You should carefully read the prospectus, the applicable
prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the
heading </I>&ldquo;<I>Risk Factors</I>&rdquo; <I>contained in this prospectus, the applicable prospectus supplement and any related free
writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, including
our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
International, Inc. (&ldquo;Dyadic&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, or the &ldquo;Company&rdquo;) is a
global biotechnology company based in Jupiter, Florida with operations in the United States and a satellite office in the Netherlands,
and it utilizes several&nbsp;third-party consultants and research organizations to carry out the Company&rsquo;s activities. Over the
past&nbsp;two&nbsp;plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial
enzymes and other proteins, and has previously licensed this technology to&nbsp;third&nbsp;parties, such as Abengoa Bioenergy, BASF,
Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the&nbsp;Thermothelomyces heterothallica&nbsp;(formerly
known as&nbsp;Myceliophthora thermophila) fungus, which the Company named&nbsp;C1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the Company selling its industrial technology business to Danisco USA (&ldquo;Danisco&rdquo;), the industrial biosciences business
of DuPont (NYSE: DD) (the &ldquo;DuPont Transaction&rdquo;) on&nbsp;December 31, 2015,&nbsp;the Company has been focused on building
the&nbsp;C1-cell protein production platform&nbsp;for the development and production of biologic products including enzymes and other
proteins for human and animal health. Some examples of human and animal vaccines and drugs which have the potential to be produced from&nbsp;C1-cells
are protein antigens, ferritin nanoparticles, virus-like particles (&ldquo;VLPs&rdquo;), monoclonal antibodies (&ldquo;mAbs&rdquo;),
Bi/Tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, as well as other therapeutic enzymes and proteins. The Company
is involved in multiple funded research collaborations with animal and human pharmaceutical companies which are designed to leverage
its&nbsp;C1-cell protein production platform to develop innovative vaccines and drugs, biosimilars and/or biobetters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&nbsp;also developed&nbsp;the Dapibus&trade; thermophilic filamentous fungal based microbial protein production platform to enable
the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical
applications, such as food, nutrition, and wellness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Delaware in September 2002. Our principal corporate offices are located at 140 Intracoastal Pointe Drive, Suite
404, Jupiter, FL 33477. Our telephone number is (561) 743-8333. Our website is www.dyadic.com. Information accessed through our website
is not incorporated into this prospectus and is not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="RMa_007"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement
and any related free writing prospectus, and discussed under the section titled &ldquo;Risk Factors&rdquo; contained in our most recent
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with
the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus,
the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with a specific offering.
The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown
or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future
results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to
anticipate results or trends in future periods. If any of these risks&nbsp;occurs, our business, business prospects, financial condition,
results of operations or cash flow could be seriously harmed. This could cause the trading price of our securities to decline, resulting
in a loss of all or part of your investment. Please also carefully read the section below titled &ldquo;Special Note Regarding Forward-Looking
Statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="RMa_008"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement
contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the
Securities Act, and Section 21E of the Exchange Act. These statements relate to future events or to our future operating or financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements
to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results
of operations and financial condition, expectations, business strategy and plans and objectives of management for future operations,
are forward-looking statements. In some cases, forward-looking statements may be identified by words such as &lsquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;design,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potentially,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;should,&rdquo; &ldquo;will&rdquo; or the negative of these terms or other similar expressions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements on our beliefs, assumptions and expectations of future performance, considering the information
currently available to us. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions,
including risks described in the section titled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus and in our most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC,
which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents
incorporated by reference and any free writing prospectus that we may authorize for use in connection with a specific offering. These
factors include, among other things: &nbsp;(1) general economic, political and market conditions; (2) our ability to generate the required
productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical
research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors;
(4) our ability to implement and successfully carry out Dyadic&rsquo;s and third parties&rsquo; research and development efforts; (5)
our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to
third party contract research organizations and other service providers to carry out our research projects for ourselves and third parties;
(7) competitive pressures and reliance on our key customers and collaborators;&nbsp;(8) our ability, and the ability of the contract
research organizations and other third-party service providers with whom we are currently working with, to advance product candidates
into, and successfully complete, preclinical studies and clinical trials; (9) the commercialization of our product candidates, if approved;
(10)&nbsp;the pharmaceutical and biotech industry, governmental regulatory and other agencies&rsquo; willingness to adopt, utilize and
approve the use of our fungal based microbial protein production&nbsp;platforms and our other technologies; (11) the risk of theft, misappropriation
or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/or Danisco
US, Inc. and VTT Technical Research Centre of Finland Ltd, and contract research organizations that we engage&nbsp;with; and (12) the
speculative nature and illiquidity of equity securities received as consideration from sub-licenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information
currently available to us. These statements are only predictions based upon our current expectations and projections about future events.
There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially
from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we
operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure
and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks
emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors
on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements we may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in the forward- looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events
and circumstances reflected in the forward- looking statements will be achieved or occur. Except as required by law, we undertake no
obligation to publicly update any forward-looking statements for any reason after the date of this prospectus or to conform these statements
to actual results or to changes in our expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement
of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and achievements
may be different from what we expect. We qualify all&nbsp;our forward-looking statements by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="RMa_009"></A><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we specify another use in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities offered
by us for general corporate purposes, including for research and development, sales and marketing initiatives and general administrative
expenses, working capital and capital expenditures, as well as potential acquisitions and other strategic transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not determined the amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have
broad discretion in the allocation of the net proceeds and investors will be relying on the judgment of our management regarding the
application of the proceeds of any sale of the securities. Pending use of the net proceeds, we intend to invest the proceeds in a variety
of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we offer a particular series of securities, we will describe the intended use of the net proceeds from that offering in a prospectus
supplement. The actual amount of net proceeds we spend on a particular use will depend on many factors, including our future revenue
growth, if any, our future capital expenditures and the amount of cash required by our operations. Many of these factors are beyond our
control. Therefore, we will retain broad discretion in the use of the net proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="RMa_010"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following description summarizes the material terms and provisions of the common stock that we may offer under this prospectus, but it
is not complete. This description is based upon, and is qualified by reference to, our Restated Certificate of Incorporation, our Third
Amended and Restated Bylaws and applicable provisions of Delaware corporate law. You should read our Restated Certificate of Incorporation
and Third Amended and Restated Bylaws, which have been publicly filed with the SEC, for the provisions that are important to you.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
Restated Certificate of Incorporation authorizes us to issue up to 100,000,000 shares of common stock, $0.001 par value per share. As
of August 6, 2023, th</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ere were&nbsp;28,811,061 shares
of common stock issued and outstanding, held by&nbsp;<FONT STYLE="background-color: white">51</FONT>&nbsp;stockholders of record. There
are currently no shares of preferred stock issued or outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I>: Holders of common stock do not have cumulative voting rights and are entitled to one vote per share on all matters to be
voted upon by stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I>:
Holders of our common stock are entitled to receive ratably, from funds legally available for the payment thereof, dividends when and
as declared by resolution of our board of directors, subject to any preferential dividend rights which may be granted to holders of any
preferred stock authorized and issued by the board of directors. Delaware law allows a corporation to pay dividends only out of surplus,
as determined under Delaware law. We do not anticipate paying any cash dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Rights</I>: Our common stock is not entitled to preemptive rights and is not subject to redemption, including sinking fund provisions,
or conversion. Upon our liquidation, dissolution or winding up, the assets, if any, legally available for distribution to stockholders
are distributable ratably among the holders of common stock after payment of all classes or series of preferred stock. The rights, preferences
and privileges of holders of common stock are subject to the preferential rights of all classes or series of preferred stock that may
be issued in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options,
Restricted Stock Units&nbsp;and Warrants Convertible into Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 8, 2023, there were outstanding options entitling the holders to purchase 5,456,447&nbsp;shares of our common stock at a weighted
average exercise price of $3.10&nbsp;per&nbsp;<FONT STYLE="background-color: white">share.&nbsp;As of August 8, 2023, there were also163,044&nbsp;unvested
restricted stock units in addition to 2,836,206&nbsp;shares of common stock available for grant&nbsp;under the 2021 Equity Incentive
Award Plan.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
are currently no outstanding warrants to purchase shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Section
203 of the Delaware General Corporation Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder,
with the following exceptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;before
such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the
stockholder becoming an interested stockholder&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;upon
closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least
85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting
stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are
directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender or exchange offer&#894; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;on
or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of
the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not
owned by the interested stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines a &ldquo;business combination&rdquo; to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any merger or consolidation involving the corporation and the interested stockholder&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested
stockholder&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder&#894;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or
series of the corporation beneficially owned by the interested stockholder&#894; or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by
or through the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an &ldquo;interested stockholder&rdquo; as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The
term &ldquo;owner&rdquo; is broadly defined to include any person that, individually, with or through that person&rsquo;s affiliates
or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately
exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the
stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose
of acquiring, holding, voting or disposing of the stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Delaware corporation may &ldquo;opt out&rdquo; of these provisions with an express provision in its original certificate of incorporation
or an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders&rsquo;
amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, Section
203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage
attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certificate
of Incorporation and Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our Restated Certificate of Incorporation and Third Amended and Restated Bylaws may delay or discourage transactions involving an
actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive
a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these
provisions could adversely affect the price of our common stock. Among other things, our Restated Certificate of Incorporation and Third
Amended and Restated Bylaws contain the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Staggered Board</I>: The board of directors is composed of three classes of directors who serve staggered three-year terms so that
only one-third of the directors are eligible for election at any annual meeting of stockholders, and cumulative voting in the
election of directors is specifically denied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Elimination of Stockholder Action by Written Consent</I>: Any action permitted to be taken by the Company&rsquo;s stockholders is
required to be effected at a duly called annual or special meeting of stockholders and cannot be effected by a written
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Special Meeting of Stockholders</I>: The Company&rsquo;s stockholders will not be permitted to call a special meeting of
stockholders, and the only business matters permitted to be conducted at any annual or special meeting of stockholders will be
business matters properly brought before that meeting in accordance with specified procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Board Vacancies and Removals</I>: The board of directors establishes the number of directors, and vacancies on the board of
directors must be filled by a majority approval of the remaining directors, and directors may not be removed by stockholder action
without cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Procedures for Stockholder Nominations and Proposals</I>: Specific procedures are established for stockholder nominations for
directors and stockholder proposals of business to be considered at an annual or special meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Amendment or Repeal of Bylaws</I>: The board of directors is empowered to adopt, amend or repeal the bylaws, while our stockholders
may adopt, amend or repeal the bylaws only upon an affirmative vote of the holders of at least two-thirds of the voting power of all
then outstanding shares of stock entitled to vote</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Undesignated Preferred Stock</I>: The board of directors has the power to designate and establish new classes of preferred stock
having terms that the board of directors determines to be advisable. If in the due exercise of its fiduciary obligations, the board
of directors were to determine that a takeover proposal was not in the Company&rsquo;s best interest, shares of common stock or
preferred stock could be issued by the board of directors without stockholder approval in one or more transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Approval of Certain Matters</I>: With respect to extraordinary matters that are brought to the Company&rsquo;s stockholders for a
vote, including the sale of all or substantially all of our assets, a merger, a consolidation, the conversion of the Company into
another type of entity or the amendment of the Restated Certificate of Incorporation, unless that matter is affirmatively
recommended by the board of directors, its approval will require the affirmative vote of the holders of at least two-thirds of the
voting power of all then outstanding shares of stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;
Choice of Forum. </I>Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the
State of Delaware is the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Company, (B)
any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of the
Company to the Company or the Company&rsquo;s stockholders, (C) any action or proceeding asserting a claim against the Company
arising pursuant to any provision of the Delaware General Corporation Law or the Company&rsquo;s Restated Certificate of
Incorporation or Third Amended and Restated Bylaws, or (D) any action or proceeding asserting a claim governed by the internal
affairs doctrine. The choice of forum provision does not apply to any actions arising under the Securities Act of 1933, as amended
or the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing provisions may be amended or repealed only with the affirmative vote of the holders of at least two-thirds of the voting power
of all then outstanding shares of stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on Liability and Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Restated Certificate of Incorporation and Third Amended and Restated Bylaws contain provisions that allow us to limit the liability of
our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors
of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability
for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
unlawful payments of dividends or unlawful stock repurchases or redemptions&#894; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
&#9679; any transaction from which the director derived an improper personal benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable
remedies such as injunctive relief or rescission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Restated Certificate of Incorporation and Third Amended and Restated Bylaws provide that we generally will indemnify our directors, officers,
employees and agents to the extent and in the manner permitted by the provisions of the General Corporation Law of the State of Delaware,
as amended from time to time. However, we may modify the extent of such indemnification by individual contracts with its directors and
officers. Any repeal or modification of these provisions approved by our stockholders will be prospective only and will not adversely
affect any limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with our directors and officers, whereby we have agreed to indemnify our directors and officers
to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which
the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director,
officer, employee or agent of Dyadic, provided that such director or officer acted in good faith and in a manner that the director or
officer reasonably believed to be in, or not opposed to, the best interest of Dyadic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and
the Exchange Act, that might be incurred by any director or officer in his capacity as such.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;DYAI.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is Continental Stock Transfer &amp; Trust Company. The transfer agent&rsquo;s address
is 1 State Street, 30th Floor, New York, NY 10004, and its telephone number is (212) 509-4000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="RMa_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, &ldquo;at the market&rdquo;
offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through one or more
underwriters or dealers (acting as principal or agent), through agents, or directly to one or more purchasers. We may distribute securities
from time to time in one or more transactions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a fixed price or prices, which may be changed&#894;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    market prices prevailing at the time of sale&#894;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    prices related to such prevailing market prices&#894;&nbsp;or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will describe the terms of the offering of the securities and the specific plan of distribution in a prospectus supplement or supplements
to this prospectus, any related free writing prospectus that we may authorize to be provided to you, an amendment to the registration
statement of which this prospectus is a part or other filings we make with the SEC under the Exchange Act that are incorporated by reference.
Such description may include, to the extent applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name or names of any underwriters, dealers, agents or other purchasers&#894;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale&#894;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    options to purchase additional shares or other options under which underwriters, dealers, agents or other purchasers may purchase
    additional securities from us&#894;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    agency fees or underwriting discounts and other items constituting agents&rsquo;&nbsp;or underwriters&rsquo;&nbsp;compensation&#894;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    public offering price&#894;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    discounts or concessions allowed or reallowed or paid to dealers&#894;&nbsp;and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    securities exchange or market on which the securities may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. The underwriters,
dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they
receive compensation. Dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation
received by them on resale of the securities may be deemed to be underwriting discounts. If such dealers or agents were deemed to be
underwriters, they may be subject to statutory liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to
time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations
of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement.
We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without
a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all the securities offered by the prospectus
supplement, other than securities covered by any option to purchase additional shares or other option. If a dealer is used in the sale
of securities, we, or an underwriter, will sell the securities to the dealer, as principal. The dealer may then resell the securities
to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the
prospectus supplement the name of the dealer and the terms of the transaction. Any public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may change from time to time. We may use underwriters, dealers or agents with whom we have a
material relationship. We will describe in the prospectus supplement, naming the underwriter, dealer or agent, and the nature of any
such relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale
of securities and we will describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement
states otherwise, the agent will act on a best-efforts basis for the period of its appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may provide agents, dealers and underwriters with indemnification against civil liabilities, including liabilities under the Securities
Act, or contribution with respect to payments that the agents or dealers or underwriters may make with respect to these liabilities.
Agents, dealers and underwriters or their affiliates may engage in transactions with, or perform services for, us in the ordinary course
of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee the liquidity of the trading markets for any securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
underwriter may be granted an option to purchase additional shares, and engage in stabilizing transactions, short-covering transactions
and penalty bids in accordance with Regulation M under the Exchange Act. An underwriter&rsquo;s option to purchase additional shares
involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions
involve purchases of the securities, either through exercise of the option to purchase additional shares or in the open market after
the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a
dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions.
Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue
any of the activities at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
underwriters or dealers or agents that are qualified market makers on the Nasdaq Global Select Market may engage in passive market making
transactions in the common stock on the Nasdaq Global Select Market in accordance with Regulation M under the Exchange Act, during the
business day prior to the pricing of the offering&nbsp;before the commencement of offers or sales of the common stock. Passive market
makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive
market maker must display its bid at a price not in excess of the highest independent bid for such security&#894; if all independent
bids are lowered below the passive market maker&rsquo;s bid, however, the passive market maker&rsquo;s bid must then be lowered when
certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which
might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In
addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties
in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related
open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings
of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in
the applicable prospectus supplement (or a post- effective amendment). In addition, we may otherwise loan or pledge securities to a financial
institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement.
Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection
with a concurrent offering of other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
anticipated date of delivery of offered securities will be set forth in the applicable prospectus supplement relating to each offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="RMa_012"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">White
&amp; Case LLP will pass upon the validity of the securities&nbsp;being registered hereby and other certain legal matters in connection
with the registration of such securities. Additional legal matters may be passed upon for us or any underwriters, dealers or agents,
by counsel that we will name in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="RMa_013"></A><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mayer
Hoffman McCann P.C, independent registered public accounting firm, has audited our financial statements included in our Annual Report
on Form 10-K for the year ended December 31, 2022, as set forth in their report, which is incorporated by reference in this prospectus
and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Mayer Hoffman McCann&rsquo;s
report, given on their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="RMa_014"></A><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all
the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus
to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are
a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus
for a copy of such contract, agreement or other document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy
statements and other information with the SEC. Our SEC filings are available for free to the public over the Internet at the SEC&rsquo;s
website at http://www.sec.gov. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including
any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of
the Exchange Act can also be accessed free of charge on the Investor section of our website. These filings will be available as soon
as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website address is http://dyadic.com/investors.
Information contained on or accessible through our website is not a part of this prospectus and is not incorporated by reference herein,
and the inclusion of our website address in this prospectus is an inactive textual reference only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%"><A HREF="#toc_01">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><A NAME="RMa_015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to
be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information
in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part
the information or documents listed below that we have filed with the SEC (Commission File No. 000-55264):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923008425/dyai20221231_10k.htm" STYLE="-sec-extract: exhibit">Form
10-K for the year ended December 31, 2022, filed with the SEC on March 29, 2023&#894;</A></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923000222/dyai20230103_8k.htm" STYLE="-sec-extract: exhibit">January 4, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/dyai20230116_8k.htm" STYLE="-sec-extract: exhibit">January
23, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923001640/dyai20230123_8k.htm" STYLE="-sec-extract: exhibit">January
24, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923004182/dyai20230220_8k.htm" STYLE="-sec-extract: exhibit">February
22, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923005594/dyai20230306_8k.htm" STYLE="-sec-extract: exhibit">March
7, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923008429/dyai20221121_8k.htm" STYLE="-sec-extract: exhibit">March
29, 2023</A> (excluding the information furnished pursuant to Item 2.02 and the related exhibits furnished pursuant to Item 9.01), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1213809/000143774923009856/dyai20230328b_8k.htm" STYLE="-sec-extract: exhibit">April
10, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/dyai20230410_8k.htm" STYLE="-sec-extract: exhibit">April
12, 2023</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923017151/dyai20230602_8k.htm" STYLE="-sec-extract: exhibit">June
13, 2023</A> (as amended on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923017505/dyai20230614_8ka.htm" STYLE="-sec-extract: exhibit">June
15, 2023</A>)&#894; <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923022782/dyai20230531_8k.htm" STYLE="-sec-extract: exhibit">August
9, 2023</A> (excluding the&nbsp;information furnished pursuant to Item 2.02 and the related exhibits furnished pursuant to Item
9.01);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923013643/dyai20230331_10q.htm" STYLE="-sec-extract: exhibit">Form
10-Q for the quarter ended March 31, 2023, filed with the SEC on May 10, 2023</A> and Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000143774923022781/dyai20230630_10q.htm" STYLE="-sec-extract: exhibit">Form
10-Q for the quarter ended June 30, 2023, filed with the SEC on August 9, 2023&#894;</A> and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the description of our common stock set forth in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1213809/000121380919000013/form8anasdaquplisting.htm" STYLE="-sec-extract: exhibit">Form
8-A, filed with the SEC on April 12, 2019,</A> including any amendments thereto or reports filed for the purposes of updating this
description.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
filings filed by us pursuant to the Exchange Act after the date of the initial filing of the registration statement of which this prospectus
is a part effective upon filing shall be deemed to be incorporated by reference into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits
filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, until we file a post-effective amendment that indicates the termination of
the offering of the securities made by this prospectus and will become a part of this prospectus from the date that such documents are
filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements
in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with
the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document
modify or replace such earlier statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information provided in and incorporated by reference into this prospectus or any prospectus supplement. We have
not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus or
any prospectus supplement is accurate as of any date other than the date on the front cover of these documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
can request a copy of any or all the reports or documents that have been incorporated by reference in this prospectus but not delivered
with this prospectus (other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this
prospectus), at no cost, by writing or telephoning us at the following address or telephone number.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dyadic
International, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">140
Intracoastal Pointe Dr., Suite 404</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
Florida, 33477</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(561)
743-8333</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="form424b5_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DYADIC
INTERNATIONAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin: 0pt auto; width: 25%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS
SUPPLEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin: 0pt auto; width: 25%"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
Managing Underwriter</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Craig-Hallum</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">,
2025</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0;^4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  2     $  0!(     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$         @ !
M.$))300"       $     #A"24T$"       $     $   )    "0      X
M0DE-!!0       0    ".$))300,      50     0   #0    G    G
M%\0   4T !@  ?_8_^  $$I&248  0(! $@ 2   _^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ )P T P$B  (1 0,1 ?_=  0 !/_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MGT>J]WKL+7#<?I,FHN;[5MKY622&R)7Q'BWZOU2DOE9)%#__V3A"24T$!@
M    !P ( 0$  0$ _^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT
M<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M             /;6  $     TRU(4" @
M                                   18W!R=    5     S9&5S8P
M 80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA9
M6@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(
M=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M   D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P
M!#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M           2<U)'0B!)14,V,3DV-BTR+C$
M                                         %A96B        #S40 !
M     1;,6%E:(                     !865H@        ;Z(  #CU   #
MD%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@
M                        9&5S8P         N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                         &1E<V,         +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                          !V:65W       3I/X %%\N !#/%  #[<P
M!!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                      */     G-I9R      0U)4(&-U<G8        $
M      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H
M &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4
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M P,# P,# P,# P,# __" !$( "< - ,!$0 "$0$#$0'_Q ##   " @,! 0
M           &"0<(  4* P0!  $% 0$               4! @,$!@ '$
M!0,"! <! 0         " P0%!@$'"  )$!$2%"$B$Q46%QD*&!$   8! @0$
M @D%         0(#! 4&!Q$( !,5%B$2%PDB%! Q05%A(R0U&""1H3)B$@ !
M @0$ @@% @<        !$0( (0,$,4$2!5%A$'&!D:&Q$Q3!T>$B,D(&\&*B
MDS05%O_:  P# 0$"$0,1    [+EKHL.B3:O)5NPAHYI:DC?!U^7QMWDV%[W:
MN*P'(-WDTVIJR=!$-!ZQG"0-$279G-0$5=#6Y23WM/Y"0/CFFU1^>)RS1NG
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MS4-'G&PL:]6BTI+SF^,(3+HIZ&JU9\@D;7<[-0?<7K:JM;3!<XN0R#6@DG'
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;.6RLM5S/\?2\S!&<PJI *)15YZ6H 8H?3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b5_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "0 3\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDTR6T,DLK!(XU+,
MQZ  9)I]9WB+_D7]3_Z]9?\ T U$Y<L')=!/1'CGCO\ :*5/,L_#,7F-RIOY
MU^4?[B]_J:X'PO\ &GQ+X<OWFFO&U6WE??+!='.3W*G^'^5<(>I^M)7X'B,\
MS#$5E7=5IK9+1+Y?YW/F98FK*7-<^O\ P)\3](\>VLK6C/;W4";Y[:8?,@]<
M]"/>O.O'G[1*Q&6R\-0[W!*M?3K\H_W%[_4UA_LY_P#(8\0?]>'_ +-7DMQ_
MQ\2_[[?SKZ;&\08YY=0G&2C*?,FTM?=:6G:_7\+'94Q53V46MW<ZWP_\6?$_
MA_5)+U=2DO?.;=-#=MO1_P /X?PKZ#^'/Q:TWX@;K9(GL]3C3?);OR". 2K=
MQS7R77JW[-__ "/5S_UY/_Z$M>?P_FV,IXRGAG/FA-ZIZ_-=C+"UZBFH7T9]
M,4445^TGT 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5!>VJWUE<6SDJDT;1L1U (Q_6IZ*32
M:LP/EOQU\#=:\*F2YL0VKZ<,G?$O[U!_M+W^HKB- \-:GXHOA::79RW<W\6T
M?*GNQZ#\:^VZ\;^.'C._\!BSL="2#3SJ*R2SW$48$F00.#ZG/7K7YAFW#F"P
M<7C.=QIK>*U>NBLWM\[GCU\)3I_O+V15\&:-H?P6,S^(==B_M/4(Q ]M -PB
M4G.3CG\3CZ5R7B[X(W<-NVK>&;I=>TN3,@6(@RJ.O&.&_G[5YA//)=3/--(\
MTKG+22-EF/N:V?"OCK6?!%P9]+NVC3J]N_S12?5?ZCFOFGF6"KP6%K4.6E'X
M6G>4;[MWT=^JT\CC]K3DN24;);=ROHGA?5?$>HFQT^PFN+D'#J%P(_\ >)^[
M^-?17PF^#[^ [A]2OKSS]1EB,1BB'[N-202,]2>.M=[H$R7VDVM]Y$<,UW"D
MTGEKC+%0?QK2K]!RGAO#8*4<1*7/+=/9+Y=_4]2AA(4WSMW84445]H>@%%%%
M !1110 4444 %%%% !1110!\>ZY_P4P\"Z#K>H:9-X6\0R2V5Q);.Z"#:Q1B
MI(S)TXJG_P /1? '_0J^(_\ OF#_ ..5^>?Q&_Y*'XH_["ES_P"C6KUOP9^P
M[\6/'WA32?$>CZ9I\VEZI;I=6SR:A&C-&PR"5)R#[5^ISR7*:%.,Z[Y;]Y6/
MGEB\3.34-?D?67_#T3X?_P#0K>)/^^8/_CE:^@?\%+_A;JER(M0L=>T5#_RV
MN+59$'_?MF/Z5\G_ /#N_P"-7_0'TO\ \&<7^-<_XQ_8B^,G@K3GOKKPF=0M
MD!9SI=PERZ@=244YQ7.LLR*H^6-17?\ ?+^L8R.KC^!^K?P_^*GA+XIZ9]O\
M*:]9:U;C&_[-("\9]'0_,I]B*Z+4;F6ST^YG@MFO)HHV=+=&"M*0,A03P">G
M-?A5X0\9>(?AKXEAU?P_J-UH>LVCX\R(E&!!Y1U/WAZJPK]7/V1OVI[/]HGP
MM+;WZ16'C#3%47]G&<)*IX$T8_ND]1V/'I7@9KD4\O7MJ3YJ?XKU\O,[,/C%
M6?)+1GFFH_\ !3CPEH^H75A?^!O$MI?6LK0SV\I@#QNIP5(W]C7O'[/W[1GA
MG]HGPW=:GH(FLKJSE\JZTV\*B>'^ZQVD@JPZ$>XZU\W?\% _V5CX@L[CXG^%
M+/.J6J#^V;.!>;B(#_7@#JZCKZCGM7Q5\"_C1K/P*^(-AXHT9S+&I$=[9;L)
M=VY/S(??N#V(^M>I2RC!9E@G6P2Y:G:]]>WSZ,YY8FK0J\M75'[=T5S?PZ^(
M&C?%'P;IGB;0+I;K3+^(2(P^\A_B1AV93D$>HKS;]JW]HZP_9Y^'[W<;1W/B
M?40T.E6+'.7QS*P_N)D$^IP.]?$TL-5K5EAXQ]]NUOZ['K2J1C#G;T,/X]_M
MN^"_@+XMB\-WEE?:]JOE>;<Q::8\6N?NJY9A\Q'.!T&,]163\'?V[=&^-WCN
MR\+>'_!.OFYFR\US*T/DVL0ZR2$-P/U)Z5^7;-KOQ%\7?\O&M^(]9N_=Y;B=
MV_Q/X"OUS_9/_9OL?V>?A^EM,L5QXIU$+-JMZO/SXXB4_P!Q.GN<GTK[',LM
MP&5X5*:YJK6FKWZNW9'ET*];$5';2)[A7(_$WXI>'OA'X?@UCQ)=_9+*>[AL
MHV R6DD8*OX#DD]@#775^6/_  4/^-H^(WQ47PCI\_F:'X9W12;#\LMVP_>'
MWVC"_G7SN4Y>\QQ*I/X5JWY'=B:WL*?-UZ'ZF(ZRHKHP9&&0P.01ZTZOFO\
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M:7_X,X_\:^N>59)0?)4J*Z[R5_P//^LXN>L8Z>A]*_\ #T;P%_T*?B/\H/\
MXY2-_P %1_ 2J3_PB?B/CGI!_P#'*^:_^'=WQJ_Z!&E_^#./_&D?_@G;\:BC
M :1I>2/^@G%_C2_L_(/^?B_\#'[;&?RO[C]1?A]XSM?B)X*T;Q+9036UIJEL
MMS%#/C>BMT#8)&?I70UP_P $/"FH>!OA'X3T#5HTBU+3K".WN$C<.H<#G!'6
MNXK\ZK*,:LE#:[MZ'N1;<4WN%%%%8E!1110 4444 ?A+\1_^2A>*?^PI<_\
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MECJRLM%^1]AZ1IL6C:596$/^IM8$@3_=50H_05;HHK\L;N[L^B/RG_X*/_\
M)R$O_8+MOY&O?_\ @EK_ ,DV\9_]A9/_ $4*\ _X*/\ _)R$O_8+MOY&O?\
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M:'],_;F">.Z@CFA=98I%#HZ'(92,@@^E?F9_P4\_Y+/X>_[ P_\ 1K5]&_\
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MB^4G)_#H.>M;1=0F_.5QG(]*^DAQ3C')THSC>-KJRNNUSS?J5!MKKZGY@_\
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MJ]=[F+_6K;PM((SZ,0,"O2J\3.%2&8SJ06ED]+/_ #,/8T(TN5OW7YGYY?\
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MQ%=!J5K+8_%CP#;3MOFATN6-VSG+  $_G7J=G;BUM88N"414) QG Q7$>//
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b5_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $< BP# 2(  A$! Q$!_\0
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M%3_"C_A%=$_Z ]A_X"I_A6I175]4P_\ S[C]R,O;5/YG]YE_\(KHG_0'L/\
MP%3_  H_X171/^@/8?\ @*G^%:E%'U3#_P#/N/W(/;5/YG]YE_\ "*Z)_P!
M>P_\!4_PH_X171/^@/8?^ J?X5J44?5,/_S[C]R#VU3^9_>9?_"*Z)_T![#_
M ,!4_P */^$5T3_H#V'_ ("I_A6I11]4P_\ S[C]R#VU3^9_>9?_  BNB?\
M0'L/_ 5/\*/^$5T3_H#V'_@*G^%:F:*/JF'_ .?<?N0>VJ?S/[S+_P"$5T3_
M * ]A_X"I_A1_P (KHG_ $![#_P%3_"M2BCZIA_^?<?N0>VJ?S/[S+_X171/
M^@/8?^ J?X4?\(KHG_0'L/\ P%3_  K4HH^J8?\ Y]Q^Y![:I_,_O,O_ (17
M1/\ H#V'_@*G^%'_  BNB?\ 0'L/_ 5/\*U**/JF'_Y]Q^Y![:I_,_O,O_A%
M=$_Z ]A_X"I_A1_PBNB?] >P_P# 5/\ "M2BCZIA_P#GW'[D'MJG\S^\R_\
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M:E.1&E=416=W(5549+$\  =S1]4P_P#S[C]R#VU7^9_>9/\ PBNB?] >P_\
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M\*U**/JF'_Y]Q^Y![:I_,_O,O_A%=$_Z ]A_X"I_A1_PBNB?] >P_P# 5/\
M"M2BCZIA_P#GW'[D'MJG\S^\R_\ A%=$_P"@/8?^ J?X4?\ "*Z)_P! >P_\
M!4_PK4HSBCZIA_\ GW'[D'MJG\S^\R_^$5T3_H#V'_@*G^%'_"*Z)_T![#_P
M%3_"M2BCZIA_^?<?N0>VJ?S/[S+_ .$5T3_H#V'_ ("I_A1_PBNB?] >P_\
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MHG180I8X,A5CG'"XQFO/]._9&BU;XD7/@VQ\8QW]SH&E'4O%5]9V+7$6G.,
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M"I-'U4WD'C:>:SN)'@VG2KF!B+F-P"=VP*[9XSMJY^S=\*_"GBW]IF_\(WD
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MGKP<>E=3I/[:'A/3OB _Q ?X2Q-XZOK1[74]3BUAUBD9HMADAB*$(S87).>
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M0RD$'N*6OICK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=A@>IZ5/L7W_K3_ # ^PO(DR1Y;9')^4\5FZ5KEIK=_JMG:>>]QI<XMKD/
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MY7=C()JW2BDVW_P?P ^BR,45D^%?%6F>-M!M]:T>9KG3+EI%AF:-D\S8[(2
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MLOQA\<?B(=3\<WEA?7>E_P#"+-9PV=LTVFPZ?/OMH9?,O!.PG99GD908MH
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MDU,-.'PZHRKBYFNY \\TD[XP&D8L<>F36?-?*[FW@5KF=OEV1\X^I[5N>'_
M.O>,9E"PM969Z^I'N?\ "O;?!GPCTKPS#&TD*37 '+$9YKU<!PW)M5<;*W]U
M;_-_Y?>;4L)]JI]Q9^$FGSZ=X.M8IT*/C.#6_P"*_"FC^.?#FH:!X@T^'5M%
MU"/R;JRN,^7,F0=K8(.,@=^U::1K$@5%"J.@%.K] N[W/3/*]$_98^$?AS1[
MG2M,\ Z59Z;<W=O?S6R>:4>> DPR'+GE"QQVY[UU]K\-/"EEJWBC4XO#]B+[
MQ0$77)7CW_VBJH442JQ(("DC&.AKI:*;G)[L#S_X;?L_?#;X.ZA>WW@KP7I7
MAR]O5\N>YM(R9&3.=@9B2JYYVK@>U,^(O[/'PS^+FKVNJ^,O!&D>(M2MD$<=
MW>0GS-@.0C%2-Z@_PMD5Z'11SROS7U$<)\0O@1\//BOI.FZ9XN\':5KECI@V
MV,4T.S[*N -L90J57  V@XXZ5<TKX0>"="U+PW?Z;X7T[3[SPW:R6.CR6T7E
M_88)/]9'& <8;OD$G)KKZ*.:5K7 \W\/?LW?"SPGX[?QIHW@+1--\4-(TPU*
M"WPR2-]YT7.U&.3EE /-:L7P9\#0>%O$7AN/PQ8IH/B.XEN]7L &\N]FE(,C
MO\V<L0,X(Z5V=%#G)[L9YQX[_9P^%_Q.CT=/%7@;2-;&D0+:V#7$;!H(5 "Q
M!E()08^ZQ(J3QW^SQ\,OB=I^D6/BCP/H^KVFD1"#3XW@\O[+%C'EH4*D)P/E
MSCVKT.BGSR5K/81P'B[]G_X;>//"^D>'->\$Z/J&AZ. NFV7D>4MD,8Q$4*E
M 1U //?-=5X6\*Z-X'\/6.A>'M,M=&T:QC\JVL;.,)%$N<X ^I))ZDGFM6BI
M<I-6; ****0!1110 4$!@00"",$$9!'I110!A>'/ 7ACP==W-UH'AS2-#N;G
M_7SZ=8Q6[R<YPS(H)&>:U-.TRSTBU%M86D%C;!F<0VT:QH&9BS-M  R6))/<
MDFK-%-MO<!2Q.,DG' SVKG-<^''A+Q1JJ:GK/A;1=7U)$6-;R_T^*:8*.57>
MRDX&3@=LUT5%)-K8#(\2>#M \96$-CK^AZ;K=E"XDBM]0M(YXXV P"JL"%..
M..U<AX@^!_A[7_&'AS4I-,TI=$TNVU&&?0SI\9@NWNO)S(5QMR##DD@DY'I7
MHU%4I-;,#)L/".A:5;:=;V6B:=9V^FJZV,5O:1HMJ'&UQ$ /DW D'&,@\U3T
MCX<>$M U=-6TOPMHNFZI'%Y"7MII\44R1XQL#JH(& !@=A7144KON!ST/PY\
M)6^ORZY%X6T6/6I91</J*:?$+AI1T<R;=V[D_-G-3:!X'\-^$[N]NM#\/Z7H
MUS?-NNIK"SC@><Y)^<J 3R2>>Y-;=%%WW ****0!1110 4444 %9EWX7T:_M
M]1@NM(L+F#4G66^BFMD9;IU"A6E!'SD!5 +9(VCT%:=>&^)_C#XFT3Q1XB\#
MQ_8CXONM<T^V\-R/;YC?3[L;FG=,_.8!#=AB."43.,U<8N3T ]6OO OAK4_$
M5MK]YX>TJ[UVV $&ISV4;W,0'W=LA&X8[<\=JAU7X;^$==UB75M2\*Z+J.J2
MQ>1)>W>GQ2S/'C&UG922,<8->!>)?C1\1H_A7K?Q/TS6_#UEH\.N-I-MX=N]
M.WR1Q+J LRSW'F FX.&?R]NT9QVS7:^'O&OCKQC?ZMXCLO$'AS1O#6G>*)]
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M /3E%7I_F/\ WF_.ANC?6+_\"7_R)BU.^Z^[_@G)_P#"S_#O_/?4/_!->_\
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MX=_Y[ZA_X)KW_P",UUGF/_>;\Z/,?^\WYT<U#^5_^!+_ .1"T^Z^[_@G)_\
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M_P"":]_^,UUGF/\ WF_.CS'_ +S?G1S4/Y7_ .!+_P"1"T^Z^[_@G)_\+/\
M#O\ SWU#_P $U[_\9H_X6?X=_P">^H?^":]_^,UUGF/_ 'F_.CS'_O-^='-0
M_E?_ ($O_D0M/NON_P""<G_PL_P[_P ]]0_\$U[_ /&:/^%G^'?^>^H?^":]
M_P#C-=9YC_WF_.CS'_O-^='-0_E?_@2_^1"T^Z^[_@G)_P#"S_#O_/?4/_!-
M>_\ QFC_ (6?X=_Y[ZA_X)KW_P",UUGF/_>;\Z/,?^\WYT<U#^5_^!+_ .1"
MT^Z^[_@G)_\ "S_#O_/?4/\ P37O_P 9H_X6?X=_Y[ZA_P"":]_^,UUGF/\
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M]TC3;;6)9_#D$<L#6<T8D$VYF& %(X(R2>!P:A4:CZ ?1-%<Q\,?B/HGQ=\
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MXP>XI*G)NU@/<**;%()8DD"N@=0VV1=K#(S@CL?44ZLP"BBB@ HHHH ****
M"BBB@ KSSQ'\=/#WAK5KRPEMM3O#:ZE!HLD]E;>9'_:$RJ\=J.<ERK*2<;1D
M G->AUY;KOP#LM8U[4]3M_$FK:7]LUJV\1I:VRQ-'!J4*H@G&Y265DC"F-B5
MY) SC%PY;^\!NV_Q8T75-6U#1K*+5UU2WCN,-<Z+=0V^Z)6)_?/&(R,KP=V&
M[9S7):#\:[ZT^!'PY\3W^FOXA\5>*X+&VM=-LF2W%U>SQER-S?+%& KLS'.
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M"+1+B'7]9UJ\T6ZTAIU+Z:]IO-U)(V/F5 J$8 W>;'TS7YD?\%B_^3FO#/\
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MW0'F,GP.B\37M]>^._$5YXVNKC3;K2(4DMH[*WM+>X7;<&*.+I(X !D8D@
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M:\\]0>+F/>/W%R 2!*A].,@5[I11[6>]P(+&T6PL;:U1Y)$MXDA5YG+NP50
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MV""0,9-1V/[0WAG5;74#:V>NP7T.ES:Q9V6I:3-:2:G;1KDR6P<#S!RN0/F
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M@HHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQV_X+%_\G->&
M?^Q0M?\ TMO:_8FOQV_X+%_\G->&?^Q0M?\ TMO:Z</\9I#<_1?]F;QI):_L
MW_"B$>%O$MP(_">DIYT%C&T;XLXAN4F494]0<#BO2?\ A.Y?^A0\5_\ @OC_
M /CM<S^RW_R;+\(O^Q0TC_TBBKT^AU*=_@_%F+4K[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4O:4_Y/Q8K2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
MQVC_ (3N7_H4/%?_ (+X_P#X[74T4>TI_P GXL+2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
MQVC_ (3N7_H4/%?_ (+X_P#X[74T4>TI_P GXL+2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
MQVC_ (3N7_H4/%?_ (+X_P#X[74T4>TI_P GXL+2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
MQVC_ (3N7_H4/%?_ (+X_P#X[74T4>TI_P GXL+2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
MQVC_ (3N7_H4/%?_ (+X_P#X[74T4>TI_P GXL+2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
MQVC_ (3N7_H4/%?_ (+X_P#X[74T4>TI_P GXL+2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
MQVC_ (3N7_H4/%?_ (+X_P#X[74T4>TI_P GXL+2[G+?\)W+_P!"AXK_ /!?
M'_\ ':/^$[E_Z%#Q7_X+X_\ X[74T4>TI_R?BPM+N<M_PG<O_0H>*_\ P7Q_
M_':/^$[E_P"A0\5_^"^/_P".UU-%'M*?\GXL+2[G+?\ "=R_]"AXK_\ !?'_
M /':/^$[E_Z%#Q7_ ."^/_X[74T4>TI_R?BPM+N<M_PG<O\ T*'BO_P7Q_\
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ME>'_ !1IWB;1(=6LY)8K*7.TW\#VL@PVTY24*PY'&1S6D\\,<@1YHD<\A&D
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MA,GRXGN S+$_ $BJ0.E?6$$Z7$4<T,BRQ2*'22-@RLI&001U!'>G9-:>V=K
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MO%FIV&H65QJB&WU!66Z6.TA0RAAALLJ \C@G/2N.KI/!_P /=:\;W*II]J1
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M +W_ .2Z/^'Q7QF_Z%GP)_X 7O\ \ET>R8<K/V(HK\=_^'Q7QF_Z%GP)_P"
M%[_\ET?\/BOC-_T+/@3_ , +W_Y+H]DPY6?L117X[_\ #XKXS?\ 0L^!/_ "
M]_\ DNC_ (?%?&;_ *%GP)_X 7O_ ,ET>R8<K/V(HK\=_P#A\5\9O^A9\"?^
M %[_ /)='_#XKXS?]"SX$_\  "]_^2Z/9,.5G[$45^.__#XKXS?]"SX$_P#
M"]_^2Z/^'Q7QF_Z%GP)_X 7O_P ET>R8<K/V(HK\=_\ A\5\9O\ H6? G_@!
M>_\ R71_P^*^,W_0L^!/_ "]_P#DNCV3#E9^Q%%?CO\ \/BOC-_T+/@3_P
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A<6BQ210F))))0Q$DDAW;IF&<@8 XZD]%"#C.[+BK,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b5_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #! TP# 2(  A$! Q$!_\0
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MZ=11S/N!YC_PSMX7_P"@U\0/_#C>(?\ Y.I&_9V\,8R-;^(&1V_X6+X@Y_\
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M# _YC?Q _P##B^(/_DZEC_9X\,,#G6?B 2.__"QO$/\ \G5Y3^SW^U=HEO\
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M\GJ:/V=O#??6?B!_X<;Q!_\ )U>I]>:6CF?<1Y9_PSMX:_Z#/Q _\.-X@_\
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M,_$#_P .-X@_^3J/^&=O#/?6?B!_X<;Q!_\ )U>I44<S[@>5I^SQX8;KK?Q
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M%U(;[Z\'_&I*.9]QGF'_  SKX7_Z#7Q _P##C>(?_DZC_AG7PO\ ]!KX@?\
MAQO$/_R=7I]%',^X'F'_  SKX7_Z#7Q _P##C>(?_DZC_AG3PO\ ]!KX@?\
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MN8X2,UP_[$@2_P#CS^T4L=U]G2>XE5;J-A^[!N[D;P?;.<^U=/9?L"ZKX/\
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M_P#Q=?IV3<#5<XP-/'1Q"BIWTY6[6;6]UV/EL;GT,'7E0=-NUM;]TGV/VO\
M*?\ N-^5(R.JDE&P/05^)Z_$?Q0Q 'BW6R?0:K/_ /%TX_$'Q6>OBG7#]=3G
M_P#BZ]I^&E?_ *"E_P" O_Y(X_\ 6>G_ ,^G]_\ P#]F]9\/Q^)-$U+3+^.4
MVNHVTEK.(R5;RW4JP!['!/-<W\'_ (,Z!\#O!P\,>%X;R/2Q<R76+R8S/O<
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MG]__  #]KO*?^XWY4>4_]QORK\4?^%A>*_\ H:M=_P#!G/\ _%T?\+"\5_\
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M_D@_UGI_\^G]_P#P#]KO*?\ N-^5(87(P4;\J_%+_A87BO\ Z&K7?_!G/_\
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MCRG_ +C?E7XH_P#"PO%?_0U:[_X,Y_\ XNC_ (6%XK_Z&K7?_!G/_P#%T_\
MB&E;_H*7_@+_ /D@_P!9Z?\ SZ?W_P# /VL>.3& C<^U"P.!]QORK\4_^%@^
M*_\ H:=<_P#!G/\ _%T?\+"\5_\ 0U:[_P"#.?\ ^+I?\0TK?]!2_P# 7_\
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M+_\ D@_UGI_\^G]__ /VN\I_[C?E36BD_N-^5?BG_P +"\5_]#5KO_@SG_\
MBZ/^%@^*S_S-.N?^#.?_ .+H_P"(:5O^@I?^ O\ ^2#_ %GI_P#/I_?_ , _
M:J."0MN*-[#%2>4_]QORK\4?^%@^*Q_S-6N_^#.?_P"+H_X6%XK_ .AJUW_P
M9S__ !='_$-*W_04O_ 7_P#)#_UGI_\ /I_?_P  _:[RG_N-^5'E/_<;\J_%
M'_A87BO_ *&K7?\ P9S_ /Q='_"PO%?_ $-6N_\ @SG_ /BZ?_$-*W_04O\
MP%__ "0O]9Z?_/I_?_P#]KO*?^XWY4TPR!LA&P?:OQ3_ .%A>*_^AJUW_P &
M<_\ \71_PL'Q7_T-6N_^#.?_ .+H_P"(:5O^@I?^ O\ ^2#_ %GI_P#/I_?_
M , _:X1/_<;\J/*?^XWY5^*/_"P?%?\ T-6N_P#@SG_^+H_X6%XK_P"AJUW_
M ,&<_P#\71_Q#2M_T%+_ ,!?_P D'^L]/_GT_O\ ^ ?M<8GQ]QORJ-XY /\
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MHV?I3Q"_]QORK\4O^%@^*_\ H:==_P#!G/\ _%T?\+!\5_\ 0U:[_P"#.?\
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M5U+ -/W::LQ=9$MV?&5+@ *2W\2D@9Q7F'[:F$_:@\=]%42VW3@#_18J]/\
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MT[C59/;#P_\  .VYT/\ PKG]G#_H&ZK_ -_;O_XJC_A7/[.'_0-U7_O[=_\
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M^_MW_P#%5R7V4?Y%'V4?Y%']E5_^@VO_ .#'_D'UJG_SXA_X"==_PKG]G/\
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MF\S/IMQFG_9E7_H.K?\ @Q_Y"^LP_P"?$/\ P$ZO_A7/[.'_ $#=5_[^W?\
M\51_PKG]G#_H&ZK_ -_;O_XJN>C\,7<FAW>K"-196MS':3%CAEE<,5&WK_ V
M?2L_[*/\BE'+:D[J..K.VC_>/R?;LQO$05KT(:_W3L?^%<_LX?\ 0-U7_O[=
M_P#Q5(WPY_9QQQIVJY_ZZW?_ ,57'_91_D4?91_D5?\ 95;_ *#:_P#X,?\
MD3]:I_\ /B'_ ("=?_PKG]G'_H':I_W]N_\ XJC_ (5S^SE_T#M4_P"_MW_\
M57(?91_D4?91_D4?V56_Z#:__@Q_Y!]:I_\ /B'_ ("=<?AS^SG_ - [5/\
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MWK'^RC_(K>&7SJ7Y,?6=NU7_ (!$J\8_%AX+_MT['_A7/[.'_0-U7_O[=_\
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MU:-QY)VR1>23DR9*[1GG=VK4@^";S:Y>6XU&:?38+.UO4GL]/>:YE6XYB00
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M33WB>P-Q:^5%.B,<LR-C.#GKCMG;'[-D!&?[>G_\!E_^*I?^&:X/^@]/_P"
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M,<8XK43XHZ=IEIH,:^)=2US4=+L-7A.J7%K(CF6>-!!MW$L1N'4],<X&*O\
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MUX1EEL[B1-$TF[T^6.)E F>;S?F0$\*/,7.>?E^E>E?\,VZ%_P!!;4ORC_\
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M!0[8B3AB<DDCISFO/'=YG:25S)*[%G=NK,3DD_4U]"?\,VZ%_P!!;4ORC_\
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M?G4)9;MX]22\L060%3Y+M'-.&C7 (7.T;2:U=<\/>,K[_A)->A\4>,[+4?\
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M/$0;,Y27"Q_=1B68G: >J[(L>^7WQ5\&Z9XH'AN[\3:;!X@WQQ?V:TW[X/(
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M_@_\C[B^TW7_ #X'_O\ K1]INO\ GP/_ '_6OAW_ (>:7_\ T3JT_P#!N_\
M\:H_X>:7_P#T3JT_\&[_ /QJC_5S,^S^^ ?VEA?Y_P '_D?<7VFZ_P"? _\
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MC25KMH0@N?+\QMREX]X&%Q]1QW]]C_D&2''<7$?^-.^WWP.?[+DS_P!?$?\
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M_GP;_O\ )1[:/9_^ R_R"Y;HJI]JNO\ GP;_ +_)1]JNO^?!O^_R4>VCV?\
MX#+_ ""Y;HJI]JNO^?!O^_R4?:KK_GP;_O\ )1[:/9_^ R_R"Y;HJI]JNO\
MGP;_ +_)1]JNO^?!O^_R4>VCV?\ X#+_ ""Y;HJI]JNO^?!O^_R4?:KK_GP;
M_O\ )1[:/9_^ R_R"Y;HJI]JNO\ GP;_ +_)1]JNO^?!O^_R4>VCV?\ X#+_
M ""Y;HJI]JNO^?!O^_R4?:;O_GP;_O\ )1[:/9_^ R_R"Y;HJI]JNO\ GP;_
M +_)1]JNO^?!O^_R4>VCV?\ X#+_ ""Y;HJI]JNO^?!O^_R4?:KK_GP;_O\
M)1[:/9_^ R_R"Y<C^^OU%5/@G_R*T_\ U]2_^A&A+JZWK_H#=?\ GLE,^"<H
M_P"$6GR"#]JEX_X$:\O'34E&U^O1K\T=%'J>BUXCX1_Y*3\7_P#L9K?_ -,F
MEU[7YJ^_Y5XGX08-\2/B^1T_X2:W_P#3)I=>=3W.E&[^SD0?AQ>#T\3>(_\
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M .VT?\8[_7.'_"I_7*1_\/-+K_HG4'_@W;_XU1_P\TNO^B=0?^#=O_C52?\
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MW_Z*(O\ X*?_ +;1_P .RW_Z*(O_ (*?_MM'_&._USA_PJ?URD?_  \TNO\
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M&2?^!$?^--%U>,/FTIS[&>+_ !J]]X^U.HY'_,_P_P @MYE#[1=?] EO^_\
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M )\'_P"_R?XT?:KG_GP?_O\ )_C7Q7_P\SA_Z)W)_P"#4?\ QJC_ (>9P_\
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MVI]JN?\ GP?_ +_)_C1]JN?^?!_^_P G^-?%?_#S.'_HG<G_ (-1_P#&J/\
MAYG#_P!$[D_\&H_^-4?ZO9G_ "O[X!_:&%_G_!_Y'VI]JN?^?!_^_P G^-'V
MJY_Y\'_[_)_C7Q7_ ,/,X?\ HG<G_@U'_P :H_X>9P_]$[D_\&H_^-4?ZO9G
M_*_O@']H87^?\'_D?:GVJY_Y\'_[_)_C1]JN?^?!_P#O\G^-?%?_  \SA_Z)
MW)_X-1_\:H_X>9P_]$[D_P#!J/\ XU1_J]F?\K^^ ?VAA?Y_P?\ D?:GVJY_
MY\'_ ._R?XT?:KG_ )\'_P"_R?XU\5_\/,X?^B=R?^#4?_&J/^'F</\ T3N3
M_P &H_\ C5'^KV9_RO[X!_:&%_G_  ?^1]J?:KG_ )\'_P"_R?XT?:KG_GP?
M_O\ )_C7Q7_P\SA_Z)W)_P"#4?\ QJC_ (>9P_\ 1.Y/_!J/_C5'^KV9_P K
M^^ ?VAA?Y_P?^1]J?:KG_GP?_O\ )_C1]JN?^?!_^_R?XU\5_P##S.'_ *)W
M)_X-1_\ &J/^'F</_1.Y/_!J/_C5'^KV9_RO[X!_:&%_G_!_Y'VI]JN?^?!_
M^_R?XT?:KG_GP?\ [_)_C7Q7_P /,X?^B=R?^#4?_&J/^'F</_1.Y/\ P:C_
M .-4?ZO9G_*_O@']H87^?\'_ )'VI]JN?^?!_P#O\G^-*+JZYQ8/_P!_D_QK
MXJ_X>9P_]$[D_P#!J/\ XU7$_%S]OG4_'_AVQM/#^@7'A+5[+48=0@U./4!-
M@QA@4*;!N5@V"#P1P16E/AS,924972[W@3+,<,E=2O\ +_@'Z%?:KG_GP?\
M[_)_C1]JN?\ GP?_ +_)_C7D/[-7[3&C_'[PZ4D$6F>+;)!]OTL-PPZ>=#GD
MQD]NJG@]B?::\2OA*V&J.E5DU)>G^1Z%.<:L5.#NF5/M5S_SX/\ ]_D_QH^U
M7/\ SX/_ -_D_P :MT5A[.7\[_#_ "-"JEU=;U_T!^O_ #U3_&D^"7/A6?(P
M?M4O'_ C5R/[Z_453^"9_P"*7G_Z^I?_ $(UY>.BXJ-Y-[]OT2-Z/4]"/2O$
MO"/_ "4CXO\ _8S6_P#Z9-+KVPG->)>$/^2D?%__ +&:W_\ 3)I=>=3W.I&]
M^SG_ ,DWN_\ L9O$?_I[O:].KP/X'?&#P'X8\&:EIFL>-O#NDZE;^)_$0FL[
M[5H(9HR=9O6&Y&<$9!!Y'0BO0/\ A?OPP_Z*/X2_\'EK_P#'*B2=V!WPI:X$
M?'WX8?\ 11_"/_@\M?\ XY2_\+^^&'_11_"7_@]M?_CE39B.]IC-AL#\:X1O
MC_\ # #/_"Q_"1]O[<M?_CE-3X^?# =?B/X1SW_XGMK_ /'*+,#OLM[49;T%
M<)_PO[X8?]%'\(_^#VU_^.4?\+^^&'_11_"/_@]M?_CE%F!W?S'T%*J[0!7!
M_P#"_OAA_P!%'\(_^#VU_P#CE'_"_OAA_P!%'\(_^#VU_P#CE%F!WM?/WC'P
M-XRU?XH_%B]T/5YM L+OPUIT"YT=+M=1D6*\W)&[$?,NX A<_?&>U>B?\+^^
M&'_11_"/_@]M?_CE'_"__AA_T4CPE_X/;7_XY5Q;CT \(DUGQ;\//AKKNE/H
MWBZ6\U3X;Z5;>'H-(L+B?R-1BLYHYX@4&+:97:%CNVY !!)7%6M>\!>+M1T7
MQOX@CU+QI:>)K?Q+ID&D?9+^Y18[%HK".Z\J#.QD8/<EF*G#*Q!!7->W#]H#
MX8C./B3X2&?^H[:__'*/^%__  P_Z*1X2_\ ![:__'*OG>]A6/(O%OAWQ=X0
M3X@Z#H+>*I?!=OJVB7.+:YN+J_\ [/D'_$S2RG=FE8_(I*HQ9=TFS!8"N8L]
M#\0>(/%FK:?H#?$*R\!7/B?P\MHU]/?02"Q\BY^V")Y")DMR^P.6(//8;:^@
M)/C_ /#%L*/B/X2QW/\ ;MK_ /'*>/C_ /#'O\2/"7_@]M?_ (Y351]@L<3I
M<7C3P'\,_B[9:!#JNH7NC:C=?\(M'J9DNYFMS;0R!8FE):95D>;8&+<KMR<8
MJSX'D\8^*KWQI96_BS7M(M8+NS?0KW6-$1WDL3 &=\2(H9GF:53NPZK$@VC.
M3UO_  O_ .&'_12/"7_@]M?_ (Y2G]H#X8GK\2/"1_[CMK_\<J.9]AV./\1S
M7O@CXQ_#;4_$#ZIXA@M]#U:PNM9L-%ED!GEFM&C#QVZ,(LJC8/ ^0UYK<P^)
M?[?T<747Q /Q"'CVW;5Y;4WG]D'1OM_R8P?L_P!E^S>7PGS[MV_^.O>?^%__
M  Q'3XD>$A]-=M?_ (Y0/V@?ACMQ_P +(\)8]/[=M?\ XY34VN@6/)?AQI-Y
MK##3_$$'C]OB#=6FIV_B-I9;F/2'+K(J#<Y$(C.8_(-MAP,;L#?7*> -%;0/
M"_PRTS7=-^(-EX0L?"Z6GV+2EU)9X/$",JS"<(?-V[0!"3^XXDQ_#7T-_P -
M ?#$@#_A9'A+ [?V[:__ !RC_AH'X8Y_Y*3X2]/^0[:__'*KVC["L?*ESX1\
M?:K\(9IM4T;Q9>^()O!WA^*=V@9]3DGBUZ6650Q&#<)%M<^G!Z8KOIY=>L-4
MUC5O!=MXZD\ :;J&AWMQ;:FMZ]Y+*ET_]H?9HK@^?)%Y!B,B#*LRG8"=V?;?
M^&@/AC_T4CPE_P"#VU_^.4']H#X8DY/Q(\)9'?\ MVU_^.4>T?8+'B\D?B#X
MI_$N-I8?&6G>"KWQA(0CF[TSSK!=#4+G[KQP-<@\?+EO0FIO"7@WQ7X<7POK
M27WBZ\U>V\=SZ1(-0OKF=#H'G3QHLD3'8T0C$3"9E+D[6+G->L?\+^^&<\ID
M;XC^$\=%!URUZ?\ ?RIA\??AB/\ FH_A+_P>VO\ \<J>=]AV/"_!G@3Q;XUL
M=,C\4W7C*T%KX!:1!'J%W9D:K]LN-KL492TZH(R V>",@C%?1?PUU#6-0^&_
MA2ZUY)5UV;2;234!<1^7(+@PJ9=ZX&UMV<C'!K)_X7]\,3_S4?PE_P"#VU_^
M.4A^/OPP/_-1_"7_ (/+7_XY2E)RZ!8[Y""HIU>?+\?OABI_Y*/X2Q_V'+7_
M ..5)_PO[X8?]%'\(_\ @]M?_CE9V8'>T5P7_"_OAA_T4?PC_P"#VU_^.4?\
M+^^&'_11_"/_ (/;7_XY19@,^.OA?6/%_P .9;#0;2+4-4BU+3K^.UEN%@$J
MV]Y#,Z^8P(4E8VQGOBO/O&WPM\:?$_5=3\3:CI>GZ'?2)I%A9:.+\7#?9[?5
M([V>::8*%W80A$7.,'YLO@>B?\+^^&'_ $4?PC_X/;7_ ..4T_'[X8,?^2C^
M$L?]ARU_^.5I&3BM$%CQ_P 1_LV:X^@F]TNTM(M83QYJ/BBZM;22W275+>62
MX$&9)HI(_-C69'595(!7 *G!I/#?P*\4>#/^$>UU_"]CXL:"76)+CPMJ&HVY
M%J][)"ZSQ/Y*6^\"%E=415 G?:3SGV/_ (7]\,/^BC^$?_![:_\ QRC_ (7]
M\,/^BC^$?_![:_\ QRJYY"L><Q^!=9^%GB+3?&R>$-%^R:5X(FT^XL]$D+_V
M;<0O)<1I;JZ[Y4;/E#;@C^[@X"Z=\-/%?A'P;\#Y])T:/7]0\+F:\U:R>]2T
MD>:YLI5E8-)P3Y\S$@]J]%'Q_P#A@#D?$CPD#_V';7_XY1_PO_X8?]%(\)?^
M#VU_^.4N=OH.QY9;_![Q7H>N6GB27PKI?BH0ZUX@O&\.W%]$N$U"6*2&Y1W4
MQF5%C>-@<?+,^#V.)XW_ &=_%MY<:==Z?H6G?9I_"H\/R>'M(O;6.TTN3SI9
M&"-=VTI,#"558Q!7_<KA2-H7V[_A?WPP_P"BC^$?_![:_P#QRC_A?WPP_P"B
MC^$?_![:_P#QRFJDNPK'DNK?LQWMQX7^)]J-.TW4=:U;2M'L=%U.[F$EQYEG
M:1Q[VE9=R$2H6#=2?FZTFH? 7Q7J'C_Q:-/TZP\/Z5K,.LDZY)=174D<]Y;^
M6D]KB-;F"0N098VD:+"G9@XQZW_PO[X8?]%'\(_^#VU_^.4?\+^^&'_11_"/
M_@]M?_CE'M)CL>>?L^?!SQ#X)\81ZSKFG'2%L=!CT..-;ZSE2X(D5B52UMH1
MY:[/D:4F3YV&!DYJR_ W7-'TO3[V#0-(UI]-\;:OXAE\.O-'%#J%O<R7(MWW
MLA031"9'57& 01D$ UZ;_P +^^&'_11_"/\ X/;7_P".5')\?OAB[ #XC^$M
MH_ZCEKS_ .1*7/*][!8\@T'X'^*O"FL6/BB3P=HGB2&2XU>7_A!C>Q);:.+R
M2!T:"21/*9L0NLF%7_7OLR,@R^'?@+XH\!-X4GG\-Z%\0DMO#TVAS:9=W:Q0
MZ2\EW)<?N#,C!X-DBP-@!]EO%@'H/7%^/OPP'_-1_"7_ (/;7_XY3O\ A?WP
MP_Z*/X1_\'MK_P#'*?M)=@L<I\&O@!'X:^&7@#3O$SWT'B#P_IT-K+!I&MW<
M5F&C=F "1R*DB\XRRDD<'->%:S:6EMKNE>$H],\,ZYK=M\4K>_?Q!%>H=6F8
MZE]H=6MM@F66.(E&8GRO*BW*Q! KZ@_X7]\,/^BC^$?_  >VO_QRJG_"YOA
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M_P 'MK_\<H_X7]\,/^BC^$?_  >VO_QRE*<I*S'8[T'%,G02J!T8'((KA?\
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M37U?_P -'>'/^@UX3_\ "GM?\:7_ (:.\.?]!OPG_P"%-:_XT?ZUXK_GXO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %>X?!K_D47_Z^G_DM%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form424b5_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ", TP# 2(  A$! Q$!_\0
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M>QV>GZ]JU[=R9V0089VP,G "^@-./'>$FU&-*;;]/\P>05TKN<?Q_P CW_\
MX9U\+_\ 0:^('_AQO$/_ ,G4?\,Z^%_^@U\0/_#C>(?_ ).KYW/QB\<J[JWB
MC459&*,I9058'!!XZ@@BC_A<?CC_ *&G4/\ OM?\*3X\P:=G2G^'^8+A_$/5
M3C^/^1]$?\,Z^%_^@U\0/_#C>(?_ ).IDO[.?AEHSLUSX@*W;_BXOB#_ .3J
M^>O^%Q^./^AIU#_OM?\ "E;XP>.T"%O$VI('&5+$ ,/;Y>:/]?,&_P#EU/\
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M )'T3_PSKX7_ .@U\0/_  XWB'_Y.H_X9U\+_P#0:^('_AQO$/\ \G5\[_\
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M^3J^>?\ A<?CC_H:=0_[[7_"C_A<?CC_ *&G4/\ OM?\*/\ 7W!?\^I_A_\
M)!_J_B/YU^/^1]#']G7PQ_T&_B!_X<7Q!_\ )U,/[._AA2"=;^(!'?\ XN+X
M@_\ DZOGS_A<?CC_ *&G4/\ OM?\*3_A<7C@_P#,T:A_WVO^%'^ON"_Y]3_#
M_P"2#_5_$?SK\?\ (^B!^SKX6(R-:^('_AQO$/\ \G4O_#.OA?\ Z#7Q _\
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MA_F'^K^(_GC^/^1]#G]G3PO_ -!OX@?^'&\0_P#R=35_9W\+[MIUKX@9[?\
M%QO$/_R=7SU_PN/QQ_T-.H?]]K_A2?\ "XO'!_YFC4/^^U_PH_U]P7_/J?X?
M_)!_J_B/YU^/^1]$_P##.OA?_H-?$#_PXWB'_P"3J/\ AG7PO_T&OB!_X<;Q
M#_\ )U?._P#PN/QQ_P!#3J'_ 'VO^%'_  N/QQ_T-.H?]]K_ (4?Z^X+_GU/
M\/\ Y(/]7\1_/'\?\CZ(_P"&=?"__0:^('_AQO$/_P G4T_L[>%_^@U\0/\
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M/YX_C_D?0C_L\>&"P1=:\?[CW_X6-X@X'_@=4O\ PSIX7_Z#7Q _\.-XA_\
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M>(O#OB+P7JNKZ!JU\^H*ENCQ3V\ID+J5;';Y?Q'<'%6?%.O7&K>&?"^C:9X
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M_"C_ (0_7O\ H":A_P" S_X5C]3Q/_/J7W/_ "-/;4OYU]Z,BBM?_A#]>_Z
MFH?^ S_X4A\(:\.NBZ@/^W9_\*/J>)_Y]2^Y_P"0>VI?SK[T9-%:W_"(:]_T
M!=0_\!G_ ,*/^$/U[_H":A_X#/\ X4?4\3_SZE]S_P @]M2_G7WHR:*U_P#A
M#]>_Z FH?^ S_P"%'_"'Z]_T!-0_\!G_ ,*/J>)_Y]2^Y_Y![:E_.OO1D45K
M_P#"'Z]_T!-0_P# 9_\ "D'A#7CTT74#_P!NS_X4?4\3_P ^I?<_\@]M2_G7
MWHR:*U_^$/U[_H":A_X#/_A1_P (?KW_ $!-0_\  9_\*/J>)_Y]2^Y_Y![:
ME_.OO1D45K_\(?KW_0$U#_P&?_"C_A#]>_Z FH?^ S_X4?4\3_SZE]S_ ,@]
MM2_G7WHR**U_^$/U[_H":A_X#/\ X4?\(?KW_0$U#_P&?_"CZGB?^?4ON?\
MD'MJ7\Z^]&116O\ \(?KW_0$U#_P&?\ PI/^$0U[_H"ZA_X#/_A1]3Q/_/J7
MW/\ R#VU+^=?>C)HK6'A#7C_ ,P74/\ P&?_  I?^$/U[_H":A_X#/\ X4?4
M\3_SZE]S_P @]M2_G7WHR**U_P#A#]>_Z FH?^ S_P"%'_"'Z]_T!-0_\!G_
M ,*/J>)_Y]2^Y_Y![:E_.OO1D45K?\(?KP_Y@FH?^ S_ .%+_P (?KW_ $!-
M0_\  9_\*/J>)_Y]2^Y_Y![:E_.OO1D45K_\(?KW_0$U#_P&?_"C_A#]>_Z
MFH?^ S_X4?4\3_SZE]S_ ,@]M2_G7WHR**U_^$/U[_H":A_X#/\ X4G_  B&
MO#_F"ZA_X#/_ (4?4\3_ ,^I?<_\@]M2_G7WHR:*U_\ A#]>_P"@)J'_ (#/
M_A1_PA^O?] 34/\ P&?_  H^IXG_ )]2^Y_Y![:E_.OO1D45K_\ "'Z]_P!
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M/_/J7W/_ "#VU+^=?>C(HK7_ .$/U[_H":A_X#/_ (4?\(?KW_0$U#_P&?\
MPH^IXG_GU+[G_D'MJ7\Z^]&116M_PB&O?] 74/\ P&?_  I?^$/U[_H":A_X
M#/\ X4?4\3_SZE]S_P @]M2_G7WHR**U_P#A#]>_Z FH?^ S_P"%'_"'Z]_T
M!-0_\!G_ ,*/J>)_Y]2^Y_Y![:E_.OO1D45K_P#"'Z]_T!-0_P# 9_\ "D_X
M1#7O^@+J'_@,_P#A1]3Q/_/J7W/_ "#VU+^=?>C)HK6_X1#7O^@+J'_@,_\
MA1_PB&O?] 74/_ 9_P#"CZGB?^?4ON?^0>VI?SK[T9-%:W_"(:]_T!=0_P#
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M_P"?4ON?^0>VI?SK[T9%%:__  A^O?\ 0$U#_P !G_PH_P"$/U[_ * FH?\
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MB"UG<K*T8S\V I Y5@!G)P:Z.;'MJTI._P#>[V\_-$<N'ZQ7W&?_ ,)9KO\
MS^_^0E_PIO\ PEFNAC_IO_D)?\*N+H,DFF)=I<6K2O8?VFMGO(F,&"6.-N,@
M*>,\X.*=>^')-/T^>Z:YM9F@M([^2WB<F58' ._&W'&>1G..:GGS"U^:7W_\
M'\-PY</V7W%/_A+-=_Y_/_(2_P"%)_PEFN_\_G_D)?\ "MB[\&W>F['N0AC2
M:"*Y6/=N@\U@%))4*>6 .TG!(S6/>VR6>I7]L"66WNIH%9AR51RHS[X%34JX
MVC'FJ3DOF_/_ "'&%"3M&*^X#XLUW_G\_P#(:_X4O_"6:[_S^_\ D)?\*@**
M10%4<&N7Z]B/^?DOO9K["E_*ON)_^$LUW_G]_P#(2_X4?\)9KO\ S^_^0E_P
MJ':M&U:/KV(_Y^2^]A]7I?RK[B;_ (2S7?\ G\_\A+_A2?\ "6ZY_P _O_D)
M?\*A*K[4TH!Z?E1]>Q'_ #\E][#V%/\ E7W$I\6ZZIS]L_\ (2_X5)_PEFN_
M\_O_ )"7_"JRHI.3^%/VK1]>Q'_/R7WL/84OY5]Q-_PEFN_\_O\ Y"7_  H_
MX2S7?^?W_P A+_A4.U:-JT?7L1_S\E][#ZO2_E7W$G_"6:Z3_P ?O3_IDO\
MA3O^$LUW_G]_\A+_ (579%/(ZTH"D4?7L1_S\E][#V%+^5?<3_\ "6:[_P _
MO_D)?\*/^$LUW_G]_P#(2_X5#M6G1(C2Q@C(+ '\Z:QV(>GM)?>P]A2_E7W$
MG_"6:[_S^_\ D)?\*0^+-<[WO_D)?\*Z/5="L+KQC_8UHUO;CS98$:T$CE'X
M"";?[]2G09-4[C0-/T^+5IKN>\,>G7<-DZPPKN>1@0Q&[&%##@GJ,>HKT9+&
MQDTJK:3:OS/HKO\  YTJ#2?)OY&.GBW7>GVWI_TR7_"G?\)9KO\ S^_^0E_P
MKH(_!=K:7-Q#>W^Q1?+912J8T.&A68.RNP)(5P"BY.0>U9C:59V^GV_GSSM?
M7273P&UA$D&(9#'SSN(8C/'0')HE',(*\IM?]O>=N_<%]7>T5]Q2_P"$LUW_
M )_?_(2_X4A\6:[_ ,_O_D)?\*Z"'P[I^I-H"0-):M<Z8;ZZ9F5E(7>3M).,
M_+CLN,'UJ"]\/Z98V-QJ$EY--8)'"0EKY<DJR2.4 8@[-HQG=GOCK1;'M751
MV_Q>2?X)A^XV<5]QC#Q7KH'_ !^_^0E_PI?^$LUW_G]_\A+_ (5K?V1:?\+,
M72]FZR8V"F,@IG?$I<XS\I)))YJEINGV;:/=:A>S7 ACNA9HMLBNV]B^"V2,
M* OU)P*B4L9&3C[5Z-KXGT5W^ U&BU?D7W%;_A+-=_Y_?_(2_P"%'_"6:[_S
M^_\ D)?\*T-:\/II5[- DKS"/6(],W%,$J]N)0V.QR<8JU;^'=/%X+:ZNKE9
M)=:N-(A,,2D#RR,2-DCU&0/7M5VQZ;BYO3^]Z^?DQ?[/:ZBON,7_ (2S7?\
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MK^Q;7_GTM_\ OTO^%(=&MUY6U@]P(UY_2C^P)?\ /S\/^"']HK^7\3PO>O\
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M+.1=J@*J(LA90/[J@\<T6I[BU/4?">I-XA\*:)JLL20S7]A;W;QH<JC21JY
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M>6SR_>F2%IG9(VQ_#N+;171?"/X0P?!^QU/3],U._OM,OIUO3;WV':.[9?\
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M\?\ @'P3_:]]_P _]W_X$/\ XT?VO??\_P#=_P#@0_\ C7WM_9EM_P ^5O\
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MI#ZT +12 Y'2EH *0D*"3T%+44I)=%(PO7/J:0"H"S%SP3^@K-F\.VCOE+6
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MKEAIE\;5)-1LW<)OC<3%$96(W)(RD;AZT?5XK["^Y!:/8[3_ (1NV_Y]X/\
MOBC_ (1NV_Y]X/\ OFO./"W[3GASQ#I#ZG>:5JWAZR.D7^N03:BL)2ZM;.;R
MIVB:.1@_5&7'#(ZL.#4&N?M0:9X>.MS7?@WQ2-.T"&QFUN]C@@9=.%U"DL:F
M/S=\C*)%#K&K%>O(H^KQVY%]R"T3TS_A&K=&_P"/>#!Z?)3AX;MO^?>#_OBO
M/=1_:0T;0+'6QXCT#6?#FKZ;-8PKH]\;?SKLWC.MJT4BRF(!FBE!+NNSRVW8
M R=_X??&70?'VA:]J*%M+;P_,T.K07$T,WV4K$)M_F0N\;H8V#!E8]P<$$4O
MJ\5]A?<@LNQTG_"-6W_/M!_WS1_PC5M_S[P?]\UP$'[1-@GA]]=U/PAXHTC1
MYK2*]TRZGM(Y!J:RR)%#%&(Y&,<TC2Q;8I=C$/G^%L33?M Z;IEOJL&L>'-<
MT?Q)83V5LOAR9(9+J[>[9DM?(>.0Q.KM'("V\!#$^[&*?U>/\B^Y!9=CN3X;
MM@"3;P #_9J!?#EO(VXV\ '8;*\I\:?M(R^$M=\*PZOX<U70;>_EU&TNM)O;
M59;^ZNH8H7MHK(QNR3^:TN 5)!Y!*[6Q=F_:&FT'Q9XZL?$'A'4=/TCPW9Z9
M,EU;R0SSW%Q>#"6HC60EI&D*QIM^7(.Y@,$GU:/\J_ +1['IW_"-VW_/O!_W
MQ1_PC=M_S[0?]\5YGJ?Q^8:G/H5SH6M>#M?LKK13<PZG:P72O!?7IMT$;1S%
M&SL<%PQV=<,1BNR^$GC&^\=>$9]4U%(8[F/5]3L MNI5?+M[V:",X)/.V-<G
MN<]*3H02NXK[@LNQM?\ "-VW_/O!_P!\4A\-VW_/O!_WQ6U14^RI_P J^X?*
MNQCCPW;$?\>\'_?-*?#=L/\ EV@_[YK809D4>IQ7A-E\;/&%KH%YXSU33="G
M\&6GB&XT:YM[,S1W]O E^;-;@,Q9)"&VNR87Y2<'(P:5"$MHK[A<J['KA\-V
MW_/O!_WQ1_PC=M_S[6__ 'Q7F^C_ !\@BU#2](N;#4]=U'4M1UF);FSM(K:"
MSMK"\$,TD^Z4X2,.OS EGQD*"=M4='_:\\#ZI ]W<K=Z5IDFEW&LV-Y-);S?
M;;6!59R(H97DB<JRLL<JJS!N.00']7C_ "+[@M$]3'AJW=O^/># Z_)4O_"-
M6W_/M!_WS7F'CCX^ZUX2\ ZQK*?#?7[/5;&73_+T_5O(2.XBNKE(=RS1RLF]
M=Q!C+!E8ID;3FNA^,/Q'UKP#X2T;4['3([-KZ]CM[^\U."2Z@T6)HW8RSI;D
MLX#*L>58*&<$L%&:/J\/Y5^ 678Z[_A&K;_GW@_[YH_X1JV_Y]X/^^:\]T?X
MZSSV7A^Q&A_\)CXEOM/?5+E/!-S%<V,=FLS1+<K-,\>1(5.V(9?*N.=I-8%A
M^U9I-PESXCGM[BW\'R^'-,U:Q@EA5+^2YN[VXMDA8,X12S11@ D!2268 '!]
M6C_(ON06CV/8?^$:MO\ GV@_[YI@\-6ZM@6T!!YX3I7F3_M5^&H](GE.F7AU
MB#58-'DTE;RR8)--"TT3&Z$_V<1LB/AC(/F&S&[BKOC?Q++XRU3X1Z99Q:EH
MW]M:F=;N[2Z0P7,=K9P-,T4J@\9F:V4C)!![@T?5X=8K[@M'L>A_\(U;?\^\
M'_?-'_"-6W_/O!_WS7G7A_XRW6N> /A-XCO6ATJ?Q9>1174$%OY\6&MYY&0,
MSJ8U_<YW_,1C&WG(MZ5^T-I-[H<_B*_\.^(-$\(#2Y]9M?$=[;(UK<VD2[B^
M(W9XBR$.BRJI=3QSQ1]7A_*ON"T>QW7_  C5M_S[P?\ ?-'_  C5M_S[P?\
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M\(Q;?\^T'_?-?#/V^\_Y^KK_ +^O_C1]OO/^?JZ_[^O_ (T?ZV4_^@?\5_\
M(A_8*_G7W?\ !/N;_A&+;_GV@_[YH_X1BV_Y]H/^^:^&?M]Y_P _5U_W]?\
MQH^WWG_/U=?]_7_QH_ULI_\ 0/\ BO\ Y$/[!7\Z^[_@GW-_PC%M_P ^T'_?
M-8-W?:'I_B^U\-W206^H7=M]HMBZX27YBI0'^]\N<=^U?&_V^\_Y^KK_ +^O
M_C33<7$LT;F6=YU8>6VYBX.>-O?.>F*RGQ6G;DH):][Z=>A4<ABOBG^'_!/N
M?_A&K7_GV@_[YH_X1JU_Y]X/^^:H?#23Q%+X,L&\4JBZL5YQ_K"G\)D'0/CK
MC^>:ZBOT*DX5:<:G):ZO9K5>I\O.FH2<=';L8W_"-6O_ #[P?]\T?\(U:_\
M/O!_WS6S16W)#LB.6/8QO^$:M?\ GW@_[YH_X1JU_P"?>#_OFMFBCDAV0<L>
MQC?\(U:_\^\'_?-'_"-6O_/O!_WS6S11R0[(.6/8QO\ A&K7_GW@_P"^:/\
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M%S@XDN9&DD08 ^3+$ =<=S4W_",6G_/"'_OFD/A>T(QY$/\ WS4N=5[I??\
M\ ->QYMHG[*OAK0M.O\ 2X-2U4Z/-I=UH]I8B.VC%C;W"%'VR)"))653M0S,
M^T>N2:W_ !A\"],\86=Q"VK:SI,LWAMO"WVG3I425;1G1V8%D.)#Y84GIAFX
MS@CJ5\,VO(,$.1_LT[_A&+3_ )X0_P#?-/VE7>R^_P#X :]CRWQU\!)_$MM\
M,?#\LUUK&E:%K'VR\U*=8+9HK".!@MCY4*(K12L(4*A<;4)/05V/B+X,:1XF
MM?'D%U<7Z)XR:W;4#$Z@Q&&-(T\K*G&1&N<YY)Z5T/\ PC%I_P \(?\ OFD/
MAJT49\B'_OFCVE7LOO\ ^ &IRWC[X%:!\1=5U;4-3>]2]U"'3T62'RR+22RE
MFEMYHU=&4MNN) P<,K+P1USJ>"?A7IW@WPUJFC22SZW%JLDCW\E[#%$)@Z",
MH(X42-$V# 55'4DY))K47PO:@<P0Y/\ LT[_ (1BT_YX0_\ ?-+GJVM9??\
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MLOO_ . %Y&M]CB_Y]H_^_8_PH^QQ?\^T?_?L?X5D_P#",6G_ #PA_P"^:/\
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MV=_FOD5&=2/PLV]K'L?RI-C?W3^58O\ PC%I_P \(?\ OFC_ (1BT_YX0_\
M?-:^]V7W_P# (]XVMC?W3^5&QO[I_*L7_A&+3_GA#_WS1_PC%I_SPA_[YH][
MLOO_ . 'O&UL;^Z?RHV-_=/Y5B_\(Q:?\\(?^^:/^$8M/^>$/_?-'O=E]_\
MP ]XVMC?W3^5&QO[I_*L7_A&+3_GA#_WS1_PC%I_SPA_[YH][LOO_P" 'O&U
ML;^Z?RHV-_=/Y5B_\(Q:?\\(?^^:/^$8M/\ GA#_ -\T>]V7W_\  #WC:V-_
M=/Y4;&_NG\JQ?^$8M/\ GA#_ -\T?\(Q:?\ /"'_ +YH][LOO_X >\;6QO[I
M_*N!\!_\CCXS_P"PBW_H*UTG_",6G_/"'_OFN4^'%K]E\7>,8U($:Z@P50.
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MZ<!D<88#-:MC\1_B1%J.L>%;WPWH%YXVCL['4;'^S[V5;#[/<3/#(\QD ?\
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MEV-_=/Y4;&_NG\J+ >5?%3XWO\-?$,&EKHRZ@);9;CS6N#'C+$8QM/I7&_\
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MB;O_ .D!?*.W_I12_P"&L9?^A8C_ / T_P#Q%'_#6,O_ $+$?_@:?_B*N_\
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M_M/QQ_T4OQ!_X Z5_P#(5)_:7CC/_)2_$'_@%I7_ ,A4?5H?RK[@Y5V/?O\
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M 'S2_P#",VO_ #PA_P"^:\!_M/QQ_P!%+\0?^ 6E?_(5+_:?CC_HI?B#_P
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M_:?CC_HI?B#_ , =*_\ D*C^T_''_12_$'_@#I7_ ,A4?5H?RK[@Y5V/??\
MA&;7_GA#_P!\T?\ ",VH_P"6$/\ WS7@7]I^./\ HI?B#_P!TK_Y"I#J?C@C
M_DI?B#_P"TK_ .0J/JT/Y5]P<J['O2>%K3)(AB /;;3O^$6M?^>,7_?->!_V
MGXX'_-2_$'_@#I7_ ,A4O]I^./\ HI?B#_P!TK_Y"H^K0_E7W!R+L>]_\(O:
M_P#/&+_OF@>%[4-GR8C]5KP3^T_''_12_$'_ ( Z5_\ (5']I^./^BE^(/\
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MWXQ_Z#T'_@+%_P#$T?\ "N_&/_0>@_\  6+_ .)K@_[3\<?]%+\0?^ .E?\
MR%1_:?CC_HI?B#_P!TK_ .0J/J5+^2/W+_(+'>'X=^, ,_V]!_X"Q?\ Q-(O
MP[\9$<Z]!_X"1?\ Q-<&=2\<'_FI?B#_ , M*_\ D*E_M/QQ_P!%+\0?^ .E
M?_(5'U*E_)'[E_D%CO/^%=>,?^@]!_X"1?\ Q-'_  KKQC_T'H/_  $B_P#B
M:X/^T_''_12_$'_@#I7_ ,A4?VGXX_Z*7X@_\ =*_P#D*CZE2_DC]R_R"QW?
M_"N_&(89UZ#'_7I%_P#$TO\ PKKQC_T'H/\ P%B_^)K@CJ?C@_\ -2_$'_@%
MI7_R%2_VGXX_Z*7X@_\  +2O_D*CZE2_DC]R_P @L=Y_PKOQC_T'H/\ P%B_
M^)H_X5WXQ_Z#T'_@+%_\37!_VGXX_P"BE^(/_ '2O_D*C^T_''_12_$'_@#I
M7_R%1]2I?R1^Y?Y!8[S_ (5WXQ_Z#T'_ ("Q?_$T?\*[\8_]!Z#_ ,!8O_B:
MX/\ M/QQ_P!%+\0?^ .E?_(5']I^./\ HI?B#_P!TK_Y"H^I4OY(_<O\@L=X
M?AWXQQ_R'H/_  $B_P#B:/\ A7?C'_H/0?\ @+%_\37!?VGXX_Z*7X@_\ =*
M_P#D*E_M/QQ_T4OQ!_X Z5_\A4?4J7\D?N7^06.\_P"%=^,?^@]!_P" L7_Q
M-'_"N_&/_0>@_P# 6+_XFN#_ +3\<?\ 12_$'_@#I7_R%1_:?CC_ **7X@_\
M =*_^0J/J5+^2/W+_(+'>#X=^,>^O09_Z](O_B:/^%=^,?\ H/0?^ L7_P 3
M7!?VGXXS_P E+\0?^ 6E?_(5+_:?CC_HI?B#_P  =*_^0J/J5+^2/W+_ ""Q
MWG_"N_&/_0>@_P# 6+_XFC_A7?C'_H/0?^ L7_Q-<'_:?CC_ **7X@_\ =*_
M^0J/[3\<?]%+\0?^ .E?_(5'U*E_)'[E_D%CO/\ A7?C'_H/0?\ @+%_\31_
MPKOQC_T'H/\ P%B_^)K@_P"T_''_ $4OQ!_X Z5_\A4?VGXX_P"BE^(/_ +2
MO_D*CZE2_DC]R_R"QW1^'7C-C\OB" #WM(O_ (FC_A7/C3_H8+?_ , XO_B:
MX3^T_' _YJ7X@_\  '2O_D*E_M/QQ_T4OQ!_X Z5_P#(5'U*E_)'[E_D%CNO
M^%<^,_\ H8+?_P  XO\ XFC_ (5UXS S_P )! ?86D7_ ,37"_VGXX_Z*7X@
M_P# '2O_ )"H_M/QQ_T4OQ!_X Z5_P#(5'U*E_)'[E_D%CNU^'GC C_D/0?^
M L7_ ,32_P#"N_&/_0>@_P# 6+_XFN"&I>-Q_P U+\0?^ 6E?_(5+_:?CC_H
MI?B#_P  =*_^0J/J5+^2/W+_ ""QWG_"N_&/_0>@_P# 6+_XFC_A7?C'_H/0
M?^ L7_Q-<'_:?CC_ **7X@_\ =*_^0J/[3\<?]%+\0?^ .E?_(5'U*E_)'[E
M_D%CO#\._&./^0]!_P" L7_Q-0R_#_QF"%37H"QZ?Z)%_P#$UQ']I^.#_P U
M+\0?^ 6E?_(5(-0\;!BP^)7B#/3/V+2O_D*E]2I?R1^Y?Y!8[[_A7?C'_H/0
M?^ L7_Q-'_"N_&/_ $'8/_ 6+_XFN#_M/QQ_T4OQ!_X Z5_\A4?VGXX_Z*7X
M@_\  '2O_D*G]2I?R1^Y?Y!8[S_A7?C'_H.P?^ L7_Q-)_PKOQCG_D/0?^ L
M7_Q-<)_:?CC_ **7X@_\ =*_^0J/[3\<?]%+\0?^ 6E?_(5'U*E_)'[E_D%C
MO/\ A7?C'_H/0?\ @+%_\32_\*[\8_\ 0>@_\!8O_B:X+^T_''_12_$'_@#I
M7_R%1_:?CC_HI?B#_P  =*_^0J/J5+^2/W+_ ""QWG_"N_&/_0>@_P# 6+_X
MFC_A7?C'_H/0?^ L7_Q-<'_:?CC_ **7X@_\ =*_^0J/[3\<?]%+\0?^ .E?
M_(5'U*E_)'[E_D%CO/\ A7?C'_H/0?\ @+%_\32-\.O&1Z:_ /\ MTB_^)KA
M/[3\<?\ 12_$'_@#I7_R%1_:?CC_ **7X@_\ =*_^0J/J5+^2/W+_(+'=?\
M"N?&?_0PP?\ @'%_\374?#_P5?>%OMTM[>+=7%W)YCLJ!03]!P*\=_M/QQ_T
M4OQ!_P" .E?_ "%1_:?CC_HI?B#_ , =*_\ D*KCA84W>$4O1!8^CY86<<OE
M>X ZBO&?!P ^(WQ>QT_X2:WQ_P""32ZY;^T_''_12_$'_@#I7_R%7I?P.^'T
M4>D>(-6U'6-2UO5-:U4WMW=WOD(Q=;:WMU"K#%&H4) G\.<Y.>:WA!Q=QI'_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form424b5_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $3 TP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZZ^%?PNT_
MXC^'=4U_7O$'CB?4KCQ%KL+&T\<ZU9PK'%JMW#$B0PW:1QJL<:*%50,+78?\
M,[>%_P#H-?$#_P .-XA_^3J/V<O^2;W?_8S>(_\ T]WM>G5RRD[O4D\Q_P"&
M=O"__0:^('_AQO$/_P G4?\ #.WA?_H-?$#_ ,.-XA_^3J].HJ>9]P/,&_9U
M\,;<C6_B!Q_U47Q!S_Y/4B_L]>%& (UWQ_@_]5&\0?\ R=7I5RQ.(5ZM]X^@
MIZ1A5  P!1S/N!YG_P ,\>%?^@YX_P#_  XWB'_Y.H_X9X\*_P#0<\?_ /AQ
MO$/_ ,G5Z=@>E+@4<S[B/,1^SMX6.<:WX_(_[*-XA_\ DZE'[.OA?_H-?$#_
M ,.-XA_^3J],'RG/:I*.9]PN>7_\,Z>%_P#H-?$#_P .-XA_^3J7_AG7PO\
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MAI>E^#-(NVAELI-GGWB9=5VL02S$KN^7  KD>-II0<6WS[6_,S]HM+=3O?\
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M?\,Z^%_^@U\0/_#C>(?_ ).I#^SIX7_Z#7Q _P##C>(?_DZO4**.9]P/+_\
MAG;PM_T&OB!_X<;Q#_\ )U'_  SMX6_Z#?Q _P##C>(?_DZO4**.9]P/+_\
MAG;PM_T&OB!_X<7Q#_\ )U5[K]GSPPA1$UOX@!F[_P#"Q?$/ _\  ZO6*CFB
M\U,=&'(/O1S/N!Y:G[/'AD]=;^('_AQ?$'_R=4@_9V\+X_Y#?Q _\.+XA_\
MDZO2(FR.>#T(J<=*.9]P/,?^&=O"_P#T&OB!_P"'&\0__)U'_#.WA?\ Z#7Q
M _\ #C>(?_DZO3J*.9]P/,#^SMX7'_,;^('_ (<7Q#_\G4P?L\^& X!UKX@$
M'_JHOB'_ .3J]08T1)SN/X4<S[B/,_\ AG?PO_T&?B#_ .'%\0__ "=2?\,[
M^&/^@S\0?_#B^(?_ ).KU*BCF?<#RW_AG?PO_P!!GX@_^'%\0_\ R=2K^SMX
M6.?^)U\0/I_PL;Q#_P#)U>HTQQCYA^-',^X'F?\ PSKX7_Z#7Q _\.-XA_\
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MM-'RG%',^XCS/_AG7PO_ -!KX@?^'&\0_P#R=1_PSKX7_P"@U\0/_#C>(?\
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MQ#=2"LG0]",BM;]H7]GGP]\'? UKXJ\*W6HV>LV%[%&]S)<EVE+9_>9X*L&
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M'2EJNID_O?I3LO\ WOTH FIKM@8'4U'F3^]^E+&2V<_>'6@!0,"GCI2 4Z@
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M:_\ @%'_ (4?ZS8+^67W+_,/KU+LSZ[4;V]A4M?'Z_M&^/%&!J-I_P" ,?\
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M:?\ @#'_ (4?ZS8+^67W+_,/KU+LSZ_I",BOD'_AH_QY_P!!&T_\ 8_\*/\
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M^T7X[!_Y"-K_ . 4?^%'^LV"_EE]R_S#Z]2[,^O5':G5\@_\-'>//^@C:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO ,VAZE=/;V$MQO0JL&I+$T,'.0Y=)"92O8(,M[9KD/$%SHFJ2ZK<)''I;P
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M_"$^(O\ H ZG_P" C_X5X-_;NM?]!G4O_ V7_P"*H_MW6O\ H,ZE_P"!LO\
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M .I?^ C_ .%'_"$^(O\ H ZG_P" C_X5X-_;NM?]!G4O_ V7_P"*H_MW6O\
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M@Q7G9_9_^(&X$^&)]P[^=%_\731^S]X_5BP\+S GJ1+#_P#%U2J8A_'0;?\
MAZZ[Z>:^Y:CO/K#\#TCQOI-MHG@;5+75O#OA_P .::WC;3/)ATF[$PN]-224
M+-(!(Q(,9SOPI.6R/EIUM\(?#&CZSJ'_  DMOIEKI=UXRCCTUX[Z,J]@T5R\
M2;D<E(7<0J6.#UZ8KS5?V?/'RG<OA:8'U$L/_P 70/V>_'RDD>%I@3Z2P_\
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MQ1_Z%"Y_\"(/_BZ0?LQ_% G \(7.?^OB#_XNCZIB/^?<ON8>SGV9Y?17J/\
MPS!\4O\ H3[G_P "(/\ XNC_ (9@^*7_ $*%S_X$0?\ Q='U3$?\^Y?<P]G/
MLSRZBO4?^&8?BC_T*%S_ .!$'_Q='_#,'Q2_Z%"Y_P# B#_XNCZIB/\ GW+[
MF'LY]F<#X8^W#Q-I)TOR?[3%W$;7[1L\L2[QL+;_ )=N<9W<>M?2EY<ZKH'C
M'PGIFLZO'?ZE#8ZN+3Q1>7T3I)JMS#N18CN)CBC("JSA1N8D  "O)V_9B^*'
M*MX0N>>QN(/_ (NFK^R[\35R%\&SC/7$\'/_ (_7?AOK&'32I2=VN]M'?:WE
MN:PYX?99W<MEXIUGQ7X,T*'Q+;:=XRB\-SVGB+6I;V*:6V@>Y8JOG;CNF$94
M#8V[YL9 R:V+/Q7KDOCKQ];6FC-)?WL>EF*TD\2)87<MO &C$SS1-^\9@=S@
M.",C.17EO_#+OQ.*A?\ A#9]H[>?!C_T.D/[+GQ-*[?^$-GV]<>?!C_T.NE5
ML3'54I?CVY>L=^K?5]"^::^R_P"OD<Q\3K;3[/XB^)(=*U&35].2^D$-]-+Y
MSS#.2QD_C.21N[XSWKF:]/\ ^&8_B@H_Y%"Y'_;Q!_\ %T)^S)\4'!*^$;DX
MX_X^(/\ XNO*GAL1.3E[)J_DS!PFW?E9YA17J/\ PS#\4?\ H4+G_P "(/\
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MIFDZ9=0:@=&DU*.RDU2[CR84WN1A ?O-G !X!/2O_P ,P_%'_H4+G_P(@_\
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M6;7^HFROHKA[> *6W,J,3SC ]20!R:Z#0=8TOQ3HUGJVD7L&HZ;>1B6"ZMI
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M=[7I]>8_LY?\DWN_^QF\1_\ I[O:].K.6[ ****0A#QS3]PQFF$X%"H2.I%
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MQ!K=_JGBFQ\ >+_'U]X7DT_P^MIJ5X+EY(9Y=8\N\-O+/'O8^1C?NR$!/0#
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MT_LP:BOPU\!>'[&QT73+[3?!.J^&]4GAP%,US:1QIRJYE3SD+DGN-V,FO>O
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M_7%?\*F._P#N&G0C()/#=,>E',^X61&NFVBC'V2W_P"_*_X4O]G6G_/I;_\
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M_GC;?]_7_P#B*\S\$?M /XEL?"FJ:OX.N_#^@>*9UM=+U47L-TGGON\J.=%
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M] W6/^_$?_Q=']IX3^9?B'M(?S'L/]L7O]V'_OZ__P 31_;%[_=A_P"_K_\
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M_%T?\->>#/\ H&ZQ_P!^(_\ XNC^TL)_,OQ#VD/YCU_^T[G_ )Y6_P#WV_\
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M;_P+;_XBOK'^T+S^Y;_D]']H7G]RW_)Z/[$PW=_?_P  /80\SY._X9'\<_\
M/?1O_ MO_B*/^&1_'/\ SWT;_P "V_\ B*^L?[0O/[EO^3T?VA>?W+?\GH_L
M3#=W]_\ P ]A#S/D[_AD?QS_ ,]]&_\  MO_ (BC_AD?QS_SWT;_ ,"V_P#B
M*^L?[0O/[EO^3T?VA>?W+?\ )Z/[$PW=_?\ \ /80\SY._X9'\<_\]]&_P#
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MM"\_N6_Y/1_:%Y_<M_R>C^Q,-W?W_P# #V$/,^3O^&1_'/\ SWT;_P "V_\
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MQC_U-Q_\ /\ [.C_ (8Q_P"IN/\ X ?_ &='_"O_ %RA^_\ ZL+_ ,-FQ_\
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M_P#IDTNN^GN:(W/V<O\ DF]W_P!C-XC_ /3W>UZ?7F'[.1!^'%X/3Q-XC_\
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M;@UTZC>A;>>V>262,Q30.X=<>6%P%)W9_AYH][M^0:'<)/J1Y(@)/)/DO_\
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M_+7&?\-D^'_^A<U7_O[%7#/,</2DX3DDUY?\ R=2$79L]M^TZA_=A_[]-_\
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M_P"A<U7_ +^Q4?\ #9/A_P#Z%S5?^_L5']J87^=?=_P ]K3[GMOVG4/[L/\
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M\9$\B;64\8YR :[HZA?*ZQD68D8$JA#[F ZD#/.,C/UI_P!MU+_GG:_]\O\
MXT[R_F'\CS^']GZRTNTT:31/%&MZ%KVFQW4/]NVBVQFN(KEUDFCDB:$P[=Z(
MR!479L7;QD'=TKX46>B^+M%\0VFMZR;S3](&BSK=W"W/]HVZNSH9WD4N9%=F
M;<K+DL0<C KH_MNI?\\[7_OE_P#&C[;J7_/.U_[Y?_&EKW TW7</0CI0C9'O
M69]MU$?\L[7_ +Y?_&HUO-19BPCMAG_9?_&IY?,+FS163]KU+^Y;?]\O_C1]
MKU+^Y;?]\O\ XT<OF%S2G.(9/]TUEC@],TV>\U$1/F.V/!_A?_&LS[9J'_/.
MW_[Y;_&N6M#5:HB3/*-.^ GB#4F\:)XR\5:;XB'BNSFL+R^M])DM[VW@(/D0
MP,9WCCBB+%@@3YFRS$DYJX_PD\=S6WB#4V^(5E!XWU'3;;1;36[30_+BL;2*
M1G9EA,S;IY#(Q+[L*=N%XKTO[9J'_/.W_P"^6_QH^V:A_P \[?\ [Y;_ !J>
M:7\R_KY$7/--*^".KZ)H'A-+#5]"L]=\*7L]SI5S'I,SVS)-$T<XN$>X:221
MR[.91(&+<G.3GMOAEX%'PY\'6^B&]_M&<7%S>7-T(1"LD\\SS2E(P2$3?(0J
MY. !R3DUJ_;-0_YYV_\ WRW^-'VS4/\ GG;_ /?+?XU,N:2LY(=S5HK*^V:A
M_P \[?\ [Y;_ !H^V:A_SSM_^^6_QK/D\T%S5HK*^V:A_P \[?\ [Y;_ !H^
MV:A_SSM_^^6_QHY/-!<U:*ROMFH?\\[?_OEO\:/MFH?\\[?_ +Y;_&CD\T%S
M5HK*^V:A_P \[?\ [Y;_ !H^V:A_SSM_^^6_QHY/-!<\B^//P+USXI^*-.U+
M2[RPMH+>R^S,MVSABV]FR,*>,$5YK_PQ_P"+_P#H*:-_W\D_^(KZG^V:A_SS
MM_\ OEO\:/MFH?\ /.W_ .^6_P :\NKE6'K3=2;U?FS"5*$G=H^6/^&/_%__
M $%-&_[^2?\ Q%'_  Q_XO\ ^@IHW_?R3_XBOJ?[9J'_ #SM_P#OEO\ &C[9
MJ'_/.W_[Y;_&LO[%PO\ 39/L(=CY8_X8_P#%_P#T%-&_[^2?_$4?\,?^+_\
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M_&C^Q<+_ $V'L(=CY8_X8_\ %_\ T%-&_P"_DG_Q%'_#'_B__H*:-_W\D_\
MB*^I_MFH?\\[?_OEO\:/MFH?\\[?_OEO\:/[%PO]-A["'8^6/^&/_%__ $%-
M&_[^2?\ Q%'_  Q_XO\ ^@IHW_?R3_XBOJ?[9J'_ #SM_P#OEO\ &C[9J'_/
M.W_[Y;_&C^Q<+_38>PAV/EC_ (8_\7_]!31O^_DG_P 11_PQ_P"+_P#H*:-_
MW\D_^(KZG^V:A_SSM_\ OEO\:/MFH?\ /.W_ .^6_P :/[%PO]-A["'8^6/^
M&/\ Q?\ ]!31O^_DG_Q%'_#'_B__ *"FC?\ ?R3_ .(KZG^V:A_SSM_^^6_Q
MH^V:A_SSM_\ OEO\:/[%PO\ 38>PAV/EC_AC_P 7_P#04T;_ +^2?_$4?\,?
M^+_^@IHW_?R3_P"(KZG^V:A_SSM_^^6_QH^V:A_SSM_^^6_QH_L7"_TV'L(=
MCY8_X8_\7_\ 04T;_OY)_P#$4?\ #'_B_P#Z"FC?]_)/_B*^I_MFH?\ /.W_
M .^6_P :/MFH?\\[?_OEO\:/[%PO]-A["'8^6/\ AC_Q?_T%-&_[^2?_ !%'
M_#'_ (O_ .@IHW_?R3_XBOJ?[9J'_/.W_P"^6_QH^V:A_P \[?\ [Y;_ !H_
ML7"_TV'L(=CY8_X8_P#%_P#T%-&_[^2?_$4?\,?^+_\ H*:-_P!_)/\ XBOJ
M?[9J'_/.W_[Y;_&C[9J'_/.W_P"^6_QH_L7"_P!-A["'8^,_&O[._BCP4FE!
MWM-5N-3NOL=O;6!=I"^TMSE0 ,#KVKZ5^"7P9MOA3I$DL\BW6OWJ*+NX0_(@
M'(B3V!ZGN?:NU:XO6D1V@M6=,[&*,2N>#@YXR*=]LU#_ )YV_P#WRW^-:X?*
MZ&'J.I%^GD5"E&#NC5HK*^V:A_SSM_\ OEO\:/MFH?\ /.W_ .^6_P :]3D\
MT;W-6BLK[9J'_/.W_P"^6_QH^V:A_P \[?\ [Y;_ !HY/-!<U:*ROMFH?\\[
M?_OEO\:/MFH?\\[?_OEO\:.3S07-6BLK[9J'_/.W_P"^6_QH^V:A_P \[?\
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M*RCRHU2-3Y2;_F.=WR@&U\4?V<M>\6^+?$6IZ3JL#67B?2;32M3M[W5+ZU2
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M9.R>@R?-%0[)O1?^^J79-_=7_OJD!*3BE0 G!J!7(D*N,-4RG'(H ^>/A_\
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MRZE_WXCH]GFW\W_I(6K_ -6.:_X;+UG_ *%?3O\ P)D_PH_X;+UG_H5]._\
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MC*LNX ON4D@8VYYKJ;7]HKP5<6UY+<W.HZ8;6UAOFCU#2[BW>>VEE2))X%=
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M%X_6MVJ\J>7*) /E/WA_6HYVNWW+_(+&?C5/^?@?]^%_QIP_M3_GX'_@.O\
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MQH_XF7_/<?\ ?E?\:^1O^&K_ !]_SUTO_P  A_C1_P -7^/O^>NE_P#@$/\
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M]G_X"@]O#S/KG_B9?\]Q_P!^5_QH_P")E_SW'_?E?\:^1O\ AJ_Q]_SUTO\
M\ A_C1_PU?X^_P">NE_^ 0_QH_MS#]G_ . H/;P\SZY_XF7_ #W'_?E?\:/^
M)E_SW'_?E?\ &OD;_AJ_Q]_SUTO_ , A_C1_PU?X^_YZZ7_X!#_&C^W,/V?_
M ("@]O#S/KG_ (F7_/<?]^5_QH_XF7_/<?\ ?E?\:^1O^&K_ !]_SUTO_P
MA_C1_P -7^/O^>NE_P#@$/\ &C^W,/V?_@*#V\/,^N?^)E_SW'_?E?\ &C_B
M9?\ /<?]^5_QKY&_X:O\??\ /72__ (?XT?\-7^/O^>NE_\ @$/\:/[<P_9_
M^ H/;P\SZY_XF7_/<?\ ?E?\:/\ B9?\]Q_WY7_&OD;_ (:O\??\]=+_ / (
M?XT?\-7^/O\ GKI?_@$/\:/[<P_9_P#@*#V\/,^N?^)E_P ]Q_WY7_&C_B9?
M\]Q_WY7_ !KY&_X:O\??\]=+_P# (?XT?\-7^/O^>NE_^ 0_QH_MS#]G_P"
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M0S9VE?)V\#G<>>.=]OM\)VK<*P'?[,/_ (JD\S4?^>Z_^ W_ -E5I);2_/\
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M\EE<D%2TCDYY.[&<5K^9J/\ SW7_ ,!O_LJ/,U'_ )[K_P" W_V55_V]^?\
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M_P#\51_:?Q"_Z!>F_P#?#_\ Q51_9.&_EC^/^0O8Q_E.3_X9(\#?\]M7_P#
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MA_\ XJC^R<-_+'\?\@]C'^4Y/_ADCP-_SVU?_P "U_\ B*/^&2/ W_/;5_\
MP+7_ .(KK/[3^(7_ $"]-_[X?_XJC^T_B%_T"]-_[X?_ .*H_LG#?RQ_'_(/
M8Q_E.3_X9(\#?\]M7_\  M?_ (BC_ADCP-_SVU?_ ,"U_P#B*ZS^T_B%_P!
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M7_XBC_ADCP-_SVU?_P "U_\ B*ZS^T_B%_T"]-_[X?\ ^*H_M/XA?] O3?\
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M\(T?^AA\6_\ A6:I_P#)%'_"-'_H8?%O_A6:I_\ )%%%%D ?\(T?^AA\6_\
MA6:I_P#)%)_PC/.?^$@\6Y]?^$KU/_Y(HHHL@%_X1H_]##XM_P#"LU3_ .2*
M/^$:/_0P^+?_  K-4_\ DBBBBR /^$:/_0P^+?\ PK-4_P#DBC_A&C_T,/BW
M_P *S5/_ )(HHHL@#_A&C_T,/BW_ ,*S5/\ Y(H_X1H_]##XM_\ "LU3_P"2
M***+( _X1H_]##XM_P#"LU3_ .2*/^$:/_0P^+?_  K-4_\ DBBBBR /^$:)
M&/\ A(?%O_A6:I_\D4?\(T?^AA\6_P#A6:I_\D44460!_P (T?\ H8?%O_A6
M:I_\D4?\(T?^AA\6_P#A6:I_\D44460!_P (T?\ H8?%O_A6:I_\D4?\(T?^
MAA\6_P#A6:I_\D44460 ?#1/7Q#XM_\ "LU3_P"2*/\ A&C_ -##XM_\*S5/
M_DBBBBR /^$:/_0P^+O_  K-4_\ DBC_ (1H_P#0P^+O_"LU3_Y(HHHL@$/A
MG)R?$'BTG_L:]3_^2*7_ (1G_J8?%O\ X5FI_P#R11119 '_  C1_P"AA\6_
M^%9JG_R11_PC1_Z&'Q;_ .%9JG_R11119 '_  C1_P"AA\6_^%9JG_R11_PC
M1_Z&'Q;_ .%9JG_R11119 '_  C1_P"AA\6_^%9JG_R11_PC1_Z&'Q;_ .%9
MJG_R11119 '_  C1_P"AA\6_^%9JG_R12'PSG_F8?%O_ (5FI_\ R11119 +
M_P (T?\ H8?%O_A6:I_\D4?\(T?^AA\7?^%9JG_R11119 '_  C1_P"AA\7?
M^%9JG_R11_PC1_Z&'Q=_X5FJ?_)%%%%D ?\ "-'_ *&'Q=_X5FJ?_)%'_"-$
MC'_"0^+<?]C9JG_R11119 '_  C9_P"AA\7?^%9JG_R11_PC;?\ 0Q>+O_"L
MU3_Y(HHHL@#_ (1MO^AB\7?^%9JG_P D4'PT3U\0^+3_ -S9JG_R11119 '_
M  C1_P"AA\6_^%9JG_R11_PC9_Z&'Q=_X5FJ?_)%%%%D ?\ "-M_T,7B[_PK
M-4_^2*/^$;/_ $,/B[_PK-4_^2***+( _P"$:/\ T,/B[_PK-4_^2*!X:(_Y
MF'Q;_P"%9JG_ ,D44460!_PC;?\ 0Q>+O_"LU3_Y(H_X1MO^AB\7?^%9JG_R
M11119 '_  C;?]#%XN_\*S5/_DBC_A&R/^9A\7?^%9JG_P D44460!_PC;?]
M#%XN_P#"LU3_ .2*/^$;;_H8O%W_ (5FJ?\ R11119 '_"-M_P!#%XN_\*S5
M/_DBC_A&V_Z&+Q=_X5FJ?_)%%%%D ?\ "-M_T,7B[_PK-4_^2*/^$;/_ $,/
MB[_PK-4_^2***+( _P"$;;_H8O%W_A6:I_\ )%'_  C;?]#%XN_\*S5/_DBB
MBBR /^$;/_0P^+O_  K-4_\ DBC_ (1L_P#0P^+O_"LU3_Y(HHHL@#_A&V_Z
M&+Q=_P"%9JG_ ,D4?\(VW_0Q>+O_  K-4_\ DBBBBR /^$;;_H8O%W_A6:I_
M\D4?\(VW_0Q>+O\ PK-4_P#DBBBBR /^$;)_YF'Q=_X5FJ?_ "11_P (V?\
MH8?%W_A6:I_\D44460!_PC9_Z&+Q=_X5FJ?_ "11_P (VW_0Q>+O_"LU3_Y(
MHHHL@#_A&S_T,7B[_P *S5/_ )(H_P"$;;_H8O%W_A6:I_\ )%%%%D ?\(VW
M_0Q>+O\ PK-4_P#DBC_A&V_Z&+Q=_P"%9JG_ ,D44460!_PC;?\ 0Q>+O_"L
MU3_Y(H_X1MO^AB\7?^%9JG_R11119 '_  C1_P"AA\6_^%9JG_R11_PC1_Z&
M'Q=_X5FJ?_)%%%%D ?\ "-'_ *&'Q=_X5FJ?_)%(?#.1@^(/%I'_ &->I_\
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M:I_\D4?\(T?^AA\6_P#A6:I_\D44460!_P (T?\ H8?%O_A6:I_\D5[/\"/
M.C:7X:U6Y2*[NKO4M2:ZN[G4+^XNYII!##$&,DSLW$<4:@9P O3K1118#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
